

10/615,659

=> d his

(FILE 'HOME' ENTERED AT 14:32:56 ON 06 OCT 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 14:33:23 ON 06 OCT 2005

L1 6829 S TESTIS(W)SPECIFIC
L2 428 S TYROSINE (W)LIGASE?
L3 3 S L1 AND L2
L4 2 DUP REM L3 (1 DUPLICATE REMOVED)
L5 7299296 S CLON? OR EXPRESS? OR RECOMBINANT
L6 89 S L2 AND L5
L7 20724 S "CPG ISLAND"
L8 12 S L6 AND L7
L9 10 DUP REM L8 (2 DUPLICATES REMOVED)
L10 41 DUP REM L6 (48 DUPLICATES REMOVED)
E FEDER J N/AU
L11 183 S E3
E WU S/AU
L12 3445 S E3
E NELSON T C/AU
L13 127 S E3
L14 3727 S L11 OR L12 OR L13
L15 1 S L2 AND L14

=>

Connecting via Winsock to .STN

Welcome to STN International! Enter x:x

LOGINID:sssptal652mxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/CAPlus -Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 OCT 03 MATHDI removed from STN
NEWS 9 OCT 04 CA/CAPlus-Canadian Intellectual Property Office (CIPO) added
to core patent offices

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:32:56 ON 06 OCT 2005

=> file medline embase biosis biotechds scisearch hcaplus ntis lifesci
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 , 0.21

FILE 'MEDLINE' ENTERED AT 14:33:23 ON 06 OCT 2005

FILE 'EMBASE' ENTERED AT 14:33:23 ON 06 OCT 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 14:33:23 ON 06 OCT 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 14:33:23 ON 06 OCT 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'SCISEARCH' ENTERED AT 14:33:23 ON 06 OCT 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'HCAPLUS' ENTERED AT 14:33:23 ON 06 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 14:33:23 ON 06 OCT 2005
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2005)

FILE 'LIFESCI' ENTERED AT 14:33:23 ON 06 OCT 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

=> s testis(w)specific
L1 6829 TESTIS(W) SPECIFIC

=> tyrosine (w)ligase?
TYROSINE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s tyrosine (w)ligase?
L2 428 TYROSINE (W) LIGASE?

=> s l1 and l2
L3 3 L1 AND L2

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 2 DUP REM L3 (1 DUPLICATE REMOVED)

=> d 1-2 ibib ab

L4 ANSWER 1 OF 2 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
DUPLICATE 1

ACCESSION NUMBER: 2004-07314 BIOTECHDS
TITLE: New testis-specific tubulin
tyrosine-ligase-like BGS-42 polypeptide,
useful for preventing, treating or ameliorating a medical
condition, e.g. aberrant cellular proliferation, reproductive
disorders or testicular disorders;
involving vector-mediated gene transfer, expression in
host cell for use in gene therapy

AUTHOR: FEDER J N; WU S; NELSON T C
PATENT ASSIGNEE: BRISTOL-MYERS SQUIBB CO
PATENT INFO: WO 2004005487 15 Jan 2004
APPLICATION INFO: WO 2003-US21605 9 Jul 2003
PRIORITY INFO: US 2002-394725 9 Jul 2002; US 2002-394725 9 Jul 2002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2004-099381 [10]

AB DERWENT ABSTRACT:
NOVELTY - A testis-specific tubulin tyrosine
-ligase-like polypeptide, designated BGS-42 polypeptide, is
new.

DETAILED DESCRIPTION - A testis-specific tubulin
tyrosine-ligase-like polypeptide, designated BGS-42
polypeptide comprises or consists of: (a) a polypeptide fragment, domain,
epitope or the full-length protein of a fully defined sequence of 541
amino acids (I), as given in the specification, or the encoded sequence
included in ATCC Deposit Number PTA-4454, having tyrosine tubulin ligase
activity; (b) a polypeptide comprising amino acids 2-541 of the sequence
of (I), where the amino acids 2-541 comprises a polypeptide of (I) minus
the start methionine; (c) a polypeptide comprising amino acids 1-541 or
73-365 of the sequence of (I); or (d) a polypeptide comprising at least
424 contiguous amino acids of the sequence of (I). INDEPENDENT CLAIMS are

also included for: (1) an isolated nucleic acid molecule comprising or consisting of: (a) a polynucleotide fragment of 1838 bp (II), fully defined in the specification, or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II); (b) a polynucleotide encoding a polypeptide fragment, domain, epitope or the full-length protein of the sequence of (I), or a polypeptide fragment, domain or epitope encoded by the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II), having tyrosine tubulin ligase activity; (c) a polynucleotide which is a variant or an allelic variant of (II); (d) nucleotides 156-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 2-541 of (I) minus the start methionine; (e) nucleotides 153-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 1-541 of (I) including the start codon; (f) nucleotides 369-1247 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 73-365 of (I); (g) a polynucleotide that encodes at least 424 contiguous amino acids of (I); (h) at least 1272 contiguous nucleotides of (II); (i) a polynucleotide which represents the complementary sequence (antisense) of (II); (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides above, where the polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A or only T residues; (k) a polynucleotide comprising or consisting of the BGS-42 gene or BGS-42 promoter; or (l) a nucleotide sequence of 2241 bp, fully defined in the specification; (2) a recombinant vector comprising the isolated nucleic acid molecule; (3) an isolated antibody that binds specifically to BGS-42 polypeptide; (4) a recombinant host cell comprising the vector sequences, or expressing the BGS-42 polypeptide; (5) making an isolated polypeptide; (6) preventing, treating or ameliorating a medical condition; and (7) diagnosing a pathological condition or a susceptibility to a pathological condition in a subject.

WIDER DISCLOSURE - Also disclosed are screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides, and methods of controlling the expression of the polypeptide.

BIOTECHNOLOGY - Preparation (claimed): The BGS-42 polypeptide is prepared by standard recombinant methods. Making an isolated polypeptide comprises culturing the recombinant host cell under conditions such that the polypeptide is expressed, and recovering the polypeptide. Preferred Polypeptide: The full-length protein comprises sequential amino acid deletions from the C-terminus or the N-terminus. Preferred Nucleic Acid: The polynucleotide fragment consists of a nucleotide sequence encoding a human tyrosine tubulin ligase. Preferred Method: Preventing, treating or ameliorating a medical condition comprises administering to a mammalian subject a therapeutic amount of the BGS-42 polypeptide or its modulator. Diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprises determining the presence or absence of a mutation in the polynucleotide cited above, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation. Alternatively, the method comprises determining the presence or amount of expression of the BGS-42 polypeptide in a tyrosine tubulin ligase sample, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

ACTIVITY - Cytostatic; Respiratory-Gen.; Gastrointestinal-Gen.; Neuroprotective; Endocrine-Gen.; Antiinflammatory; Anabolic; Hypertensive; Osteopathic; Nootropic; Antiparkinsonian; Antiarthritic; Antiasthmatic; Anti-HIV; Antibacterial; Immunosuppressive; Antiseborrheic; Dermatological. No biological data given.

MECHANISM OF ACTION - Tyrosine Ligase Modulator; Gene Therapy. No biological data given.

USE - The BGS-42 polypeptide or polynucleotide can be used for diagnosing a pathological condition or a susceptibility to a pathological condition in a subject, and for preventing, treating or ameliorating a medical condition, such as a disorder related to aberrant tubulin ligase activity, a disorder related to aberrant tubulin-carboxypeptidase activity, aberrant cellular proliferation, reproductive disorders,

testicular disorders, testicular cancer, pulmonary disorders, lung cancer, gastrointestinal disorders, colon cancer, stomach cancer, neural disorders, brain cancer, liver cancer, or proliferative condition of the testis, lung, small intestine, brain or lymph tissue (all claimed). The BGS-42 polypeptide, polynucleotide, or their modulators are also useful for treating infertility, Cushing's syndrome, emphysema, pneumonia, Addison's disease, acromegaly, Alzheimer's disease, or Parkinson's disease. The BGS-42 polypeptide can be used as a preventive agent for immunological disorders including arthritis, asthma, AIDS, sepsis, acne, Sjogren's disease or scleroderma. The antibodies may be used to purify, detect and target the BGS-42 polypeptides.

ADMINISTRATION - Administration of the antibody is 0.1-100 (preferably 1-10) mg/kg, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, intranasally, epidurally, intraventricularly, intrathecally, topically, orally, or rectally.

EXAMPLE - A polynucleotide encoding a BGS-42 polypeptide was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence to synthesize insertion fragments. The pQE-9 vector was digested with BamHI and XbaI and the amplified fragment was ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial ribosome-binding site. The ligation mixture was used to transform *Escherichia coli* strain M15/rep4. Transformants were identified by their ability to grow on LB (Luria bertani) plates, and ampicillin/kanamycin-resistant colonies were selected. Clones containing the desired constructs were grown overnight in liquid culture, i.e. LB media, supplemented with both ampicillin and kanamycin. Isopropyl-B-D-thiogalacto pyranoside (IPTG) was added to induce gene expression. Cells were grown for an extra 3-4 hours, and cells were harvested by centrifugation. The cell pellet obtained by centrifugation was solubilized, and the solubilized BGS-42 protein was purified using a metal chelating column under conditions that allow tight binding of the protein. (343 pages)

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:722839 HCAPLUS

DOCUMENT NUMBER: 141:238811

TITLE: Protein and cDNA sequences of a novel human testis-specific tubulin

tyrosine ligase like protein BGS-42, and diagnostic and therapeutic use
INVENTOR(S): Feder, John N.; Nelson, Thomas C.; Wu, Shujian; Krystek, Stanley R.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 199 pp., Cont.-in-part of U.S. Ser. No. 615,659.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004171131	A1	20040902	US 2003-635977	20030807
US 2004157234	A1	20040812	US 2003-615659	20030709
PRIORITY APPLN. INFO.:			US 2002-394725P	P 20020709
			US 2003-615659	A2 20030709

AB The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

=> d his

(FILE 'HOME' ENTERED AT 14:32:56 ON 06 OCT 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 14:33:23 ON 06 OCT 2005

L1 6829 S TESTIS(W)SPECIFIC
L2 428 S TYROSINE (W)LIGASE?
L3 3 S L1 AND L2
L4 2 DUP REM L3 (1 DUPLICATE REMOVED)

=> s clon? or express? or recombinant
L5 7299296 CLON? OR EXPRESS? OR RECOMBINANT

=> s l2 and l5
L6 89 L2 AND L5

=> s "cpG island"
L7 20724 "CPG ISLAND"

=> s l6 and l7
L8 12 L6 AND L7

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9 10 DUP REM L8 (2 DUPLICATES REMOVED)

=> d 1-10 ibib ab

L9 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:156228 HCAPLUS
Correction of: 2005:16967

DOCUMENT NUMBER: 142:192331
Correction of: 142:108390

TITLE: Quantitative RT-PCR method for the detection in blood of microarray-identified rheumatoid arthritis-related gene transcripts for diagnosing and monitoring disease state

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005003394	A1	20050106	US 2004-812782	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005003394	A1	20050106	US 2004-812782	20040330
US 2005003394	A1	20050106	US 2004-812782	20040330

PRIORITY APPLN. INFO.:
US 1999-115125P P 19990106
US 2000-477148 B1 20000104
US 2002-268730 A2 20021009
US 2003-601518 A2 20030620
US 2004-802875 A2 20040312
US 2004-812782 A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood for diagnosing and monitoring diseases. The present invention demonstrates that a simple

drop of blood may be used to determine the quant. expression of various mRNAs that reflect the health/disease state of the subject through the use of quant. reverse transcription-polymerase chain reaction (QRT-PCR) anal. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring rheumatoid arthritis using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L9 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:497356 HCAPLUS

DOCUMENT NUMBER: 143:39118

TITLE: Gene expression profiling for diagnosis, prognosis, and therapy of osteoarthritis and other diseases using microarrays

INVENTOR(S): Liew, Choong-chin

PATENT ASSIGNEE(S): ChondroGene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 157 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005123938	A1	20050609	US 2004-809675	20040325
US 2004037841	A1	20040226	US 2002-85783	20020228
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2005123938	A1	20050609	US 2004-809675	20040325
US 2005123938	A1	20050609	US 2004-809675	20040325
US 2004248169	A1	20041209	US 2004-812737	20040330
WO 2004112589	A2	20041229	WO 2004-US20836	20040621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
US 1999-115125P P 19990106
US 2000-477148 B1 20000104
US 2001-271955P P 20010228
US 2001-275017P P 20010312
US 2001-305340P P 20010713
US 2002-85783 A2 20020228
US 2002-268730 A2 20021009
US 2003-601518 A2 20030620
US 2004-802875 A2 20040312
US 2004-809675 A 20040325

AB The present invention relates to gene expression profiling for diagnosis, prognosis and therapy of osteoarthritis and other diseases using microarray methods. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy,

systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L9 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:325595 HCAPLUS

DOCUMENT NUMBER: 142:353388

TITLE: Gene **expression** profiles and biomarkers for the detection of Alzheimer's disease-related and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-chin

PATENT ASSIGNEE(S): Chondrogene Ltd., Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005079514	A1	20050414	US 2004-812827	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
PRIORITY APPLN. INFO..			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular Alzheimer's disease, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L9 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:160724 HCAPLUS

DOCUMENT NUMBER: 142:259424

TITLE: Gene **expression** profiles and biomarkers for the detection of asthma-related and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S. Ser. No. 802,875.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 47
PATENT INFORMATION:

CODEN: USXXCO

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005042630	A1	20050224	US 2004-816357	20040401
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005042630	A1	20050224	US 2004-816357	20040401
US 2005042630	A1	20050224	US 2004-816357	20040401

PRIORITY APPLN. INFO.:

US 1999-115125P	P	19990106
US 2000-477148	B1	20000104
US 2002-268730	A2	20021009
US 2003-601518	A2	20030620
US 2004-802875	A2	20040312
US 2004-816357	A	20040401

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular asthma, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L9 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2005:156681 HCAPLUS
Correction of: 2005:60757

DOCUMENT NUMBER: 142:216629
Correction of: 142:132329

TITLE: Gene expression profiles and biomarkers for the detection of hyperlipidemia and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 47
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318

US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812777	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular hyperlipidemia, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L9 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:1997 HCAPLUS

DOCUMENT NUMBER: 142:111841

TITLE: Gene **expression** profiles and biomarkers for the detection of depression-related and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): ChondroGene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265868	A1	20041230	US 2004-812702	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2004265868	A1	20041230	US 2004-812702	20040330
US 2004265868	A1	20041230	US 2004-812702	20040330

PRIORITY APPLN. INFO.:		US 1999-115125P	P 19990106
		US 2000-477148	B1 20000104
		US 2002-268730	A2 20021009
		US 2003-601518	A2 20030620
		US 2004-802875	A2 20040312
		US 2004-812702	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular mental depression, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis,

osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L9 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:60760 HCAPLUS

Correction of: 2004:1036573

DOCUMENT NUMBER: 142:153477

Correction of: 142:16776

TITLE: Gene expression profiles and biomarkers for the detection of Chagas disease and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): ChondroGene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241729	A1	20041202	US 2004-813097	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241729	A1	20041202	US 2004-813097	20040330
US 2004241729	A1	20041202	US 2004-813097	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330

PRIORITY APPLN. INFO.:

US 1999-115125P	P	19990106
US 2000-477148	B1	20000104
US 2002-268730	A2	20021009
US 2003-601518	A2	20030620
US 2004-802875	A2	20040312
US 2004-813097	A	20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular Chagas disease, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L9 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:60759 HCAPLUS

Correction of: 2004:1036572

DOCUMENT NUMBER: 142:111840

Correction of: 142:16824

TITLE: Gene expression profiles and biomarkers for the detection of lung disease-related and other

INVENTOR(S): disease-related gene transcripts in blood
 Liew, Choong-Chin
 PATENT ASSIGNEE(S): ChondroGene Limited, Can.
 SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S.
 Ser. No. 802,875.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 47
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812764	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L9 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005:60754 HCAPLUS

DOCUMENT NUMBER: 142:233342
 Correction of: 2004:1036571
 Correction of: 142:16836

TITLE: Sequences of human schizophrenia related genes and use for diagnosis, prognosis and therapy

INVENTOR(S): Liew, Choong-Chin
 PATENT ASSIGNEE(S): ChondroGene Limited, Can.
 SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S.
 Ser. No. 802,875.
 CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 47
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318

US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005208519	A1	20050922	US 2004-989191	20041115
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812731	A 20040330
			WO 2004-US20836	A2 20040621

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L9 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:60755 HCAPLUS

Correction of: 2004:1036570

DOCUMENT NUMBER: 142:154259

Correction of: 142:36938

TITLE: Analysis of genetic information contained in peripheral blood for diagnosis, prognosis and monitoring treatment of allergy, infection and genetic disease in human

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330

PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812707	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular allergy, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2,

hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

=> d his

(FILE 'HOME' ENTERED AT 14:32:56 ON 06 OCT 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 14:33:23 ON 06 OCT 2005

L1 6829 S TESTIS(W)SPECIFIC
 L2 428 S TYROSINE (W)LIGASE?
 L3 3 S L1 AND L2
 L4 2 DUP REM L3 (1 DUPLICATE REMOVED)
 L5 7299296 S CLON? OR EXPRESS? OR RECOMBINANT
 L6 89 S L2 AND L5
 L7 20724 S "CPG ISLAND"
 L8 12 S L6 AND L7
 L9 10 DUP REM L8 (2 DUPLICATES REMOVED)

=> dup rem l6

PROCESSING COMPLETED FOR L6

L10 41 DUP REM L6 (48 DUPLICATES REMOVED)

=> d 1-41 ibib ab

L10 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:156228 HCAPLUS
 Correction of: 2005:16967

DOCUMENT NUMBER: 142:192331
 Correction of: 142:108390

TITLE: Quantitative RT-PCR method for the detection in blood of microarray-identified rheumatoid arthritis-related gene transcripts for diagnosing and monitoring disease state

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005003394	A1	20050106	US 2004-812782	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005003394	A1	20050106	US 2004-812782	20040330
US 2005003394	A1	20050106	US 2004-812782	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood for diagnosing and monitoring diseases. The present invention demonstrates that a simple drop of blood may be used to determine the quant. **expression** of various mRNAs that reflect the health/disease state of the subject through the use of quant. reverse transcription-polymerase chain reaction (QRT-PCR) anal. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring rheumatoid arthritis using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L10 ANSWER 2 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:984082 HCAPLUS
TITLE: Human glucocorticoid receptor coactivator STAMP
modulating glucocorticoid-responsive gene
expression, its orangutan and green monkey
homolog, and therapeutic use thereof
INVENTOR(S): Simons, S. Stoney, Jr.; He, Yuanzheng
PATENT ASSIGNEE(S): Government of the United States of America as
Represented by the Secretary of the Department of
Health and Human Services, USA
SOURCE: PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082935	A1	20050909	WO 2005-US6393	20050225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2004-548039P P 20040226

AB The invention provides a new glucocorticoid receptor (GR) coactivator named STAMP (SRC-1 and TIF2 Associated Modulatory Protein) that can modulate transcription of glucocorticoid-responsive genes. The isolated STAMP gene is located on chromosome 14q24.3 and contains 32 introns, and its encodes a 1277 amino acid protein (predominant form, with predicted mol. weight of 143 kDa) or a 1281 amino acid protein with four extra amino acid at N-terminus. Activity of STAMP in GR-mediated induction. STAMP and TIF2 act cooperatively to modulate glucocorticoid receptor activity and STAMP activity requires the RID (receptor interaction domain) domains (around residues 834-1277) that mediate TIF2 binding to GR and/or STAMP. Also provided are siRNAs shown to inhibit STAMP actions. The invention also provides antibodies that can bind STAMP and modulate its activity. In addition, the invention provides antisense, ribozyme and siRNA STAMP nucleic acids that can modulate the **expression** of STAMP. Also provided are comps. and methods for modulating glucocorticoid-responsive gene **expression** and for treating a variety of diseases and conditions.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:497356 HCAPLUS

DOCUMENT NUMBER: 143:39118
 TITLE: Gene **expression** profiling for diagnosis, prognosis, and therapy of osteoarthritis and other diseases using microarrays
 INVENTOR(S): Liew, Choong-chin
 PATENT ASSIGNEE(S): ChondroGene Limited, Can.
 SOURCE: U.S. Pat. Appl. Publ., 157 pp., Cont.-in-part of U.S. Ser. No. 802,875.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 47
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005123938	A1	20050609	US 2004-809675	20040325
US 2004037841	A1	20040226	US 2002-85783	20020228
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2005123938	A1	20050609	US 2004-809675	20040325
US 2005123938	A1	20050609	US 2004-809675	20040325
US 2004248169	A1	20041209	US 2004-812737	20040330
WO 2004112589	A2	20041229	WO 2004-US20836	20040621

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
 US 1999-115125P P 19990106
 US 2000-477148 B1 20000104
 US 2001-271955P P 20010228
 US 2001-275017P P 20010312
 US 2001-305340P P 20010713
 US 2002-85783 A2 20020228
 US 2002-268730 A2 20021009
 US 2003-601518 A2 20030620
 US 2004-802875 A2 20040312
 US 2004-809675 A 20040325

AB The present invention relates to gene **expression** profiling for diagnosis, prognosis and therapy of osteoarthritis and other diseases using microarray methods. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used todetect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

ACCESSION NUMBER: 2005:325595 HCAPLUS
 DOCUMENT NUMBER: 142:353388
 TITLE: Gene **expression** profiles and biomarkers for the detection of Alzheimer's disease-related and other disease-related gene transcripts in blood
 INVENTOR(S): Liew, Choong-chin
 PATENT ASSIGNEE(S): Chondrogene Ltd., Can.
 SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 47
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005079514	A1	20050414	US 2004-812827	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular Alzheimer's disease, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L10 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:160724 HCAPLUS
 DOCUMENT NUMBER: 142:259424
 TITLE: Gene **expression** profiles and biomarkers for the detection of asthma-related and other disease-related gene transcripts in blood
 INVENTOR(S): Liew, Choong-Chin
 PATENT ASSIGNEE(S): Chondrogene Limited, Can.
 SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S. Ser. No. 802,875.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 47
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005042630	A1	20050224	US 2004-816357	20040401
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318

US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005042630	A1	20050224	US 2004-816357	20040401
US 2005042630	A1	20050224	US 2004-816357	20040401
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-816357	A 20040401

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular asthma, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L10 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:499078 HCAPLUS

DOCUMENT NUMBER: 143:23514

TITLE: A vital role of tubulin-tyrosine-ligase for neuronal organization

AUTHOR(S): Erck, Christian; Peris, Leticia; Andrieux, Annie; Meissirel, Claire; Gruber, Achim D.; Vernet, Muriel; Schweitzer, Annie; Saoudi, Yasmina; Pointu, Herve; Bosc, Christophe; Salin, Paul A.; Job, Didier; Wehland, Juergen

CORPORATE SOURCE: Department of Cell Biology, German Research Center for Biotechnology, Braunschweig, D-38124, Germany

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2005), 102(22), 7853-7858
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Tubulin is subject to a special cycle of detyrosination/tyrosination in which the C-terminal tyrosine of α -tubulin is cyclically removed by a carboxypeptidase and readded by a tubulin-tyrosine-ligase (TTL). This tyrosination cycle is conserved in evolution, yet its physiol. importance is unknown. Here, we find that TTL suppression in mice causes perinatal death. A minor pool of tyrosinated (Tyr-)tubulin persists in TTL null tissues, being present mainly in dividing TTL null cells where it originates from tubulin synthesis, but it is lacking in postmitotic TTL null cells such as neurons, which is apparently deleterious because early death in TTL null mice is, at least in part, accounted for by a disorganization of neuronal networks, including a disruption of the cortico-thalamic loop. Correlatively, cultured TTL null neurons display morphogenetic anomalies including an accelerated and erratic time course of neurite outgrowth and a premature axonal differentiation. These anomalies may involve a mislocalization of CLIP170, which we find lacking in neurite extensions and growth cones of TTL null neurons. Our results demonstrate a vital role of TTL for neuronal organization and suggest a requirement of Tyr-tubulin for proper control of neurite extensions.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2005:276126 SCISEARCH

THE GENUINE ARTICLE: 902DT

TITLE: Global effects of BCR/ABL and TEL/PDGFR beta **expression** on the proteome and phosphoproteome - Identification of the rho pathway as a target of BCR/ABL
AUTHOR: Unwin R D; Sternberg D W; Lu Y N; Pierce A; Gilliland D G; Whetton A D (Reprint)

CORPORATE SOURCE: Univ Manchester, Christie Hosp, Fac Med & Human Sci, Manchester M20 9BX, Lancs, England (Reprint); Univ Manchester, Fac Med & Human Sci, Manchester M20 9BX, Lancs, England; Christie Hosp, Paterson Inst Canc Res, Inst Mass Spectrometry, Manchester M20 9BX, Lancs, England; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Mt Sinai Sch Med, New York, NY 10029 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
awhetton@picr.man.ac.uk

COUNTRY OF AUTHOR: England; USA

SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (25 FEB 2005) Vol. 280, No. 8, pp. 6316-6326.
ISSN: 0021-9258.

PUBLISHER: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 80

ENTRY DATE: Entered STN: 18 Mar 2005

Last Updated on STN: 18 Mar 2005

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Many leukemic oncogenes form as a consequence of gene fusions or mutation that result in the activation or overexpression of a tyrosine kinase. To identify commonalities and differences in the action of two such kinases, breakpoint cluster region (BCR)/ABL and TEL/PDGFRbeta, two-dimensional gel electrophoresis was employed to characterize their effects on the proteome. While both oncogenes affected **expression** of specific proteins, few common effects were observed. A number of proteins whose **expression** is altered by BCR/ABL, including gelsolin and stathmin, are related to cytoskeletal function whereas no such changes were seen in TEL/PDGFRbeta-transfected cells. Treatment of cells with the kinase inhibitor STI571 for 4-h reversed changes in **expression** of some of these cytoskeletal proteins. Correspondingly, BCR/ABL-transfected cells were less responsive to chemotactic and chemokinetic stimuli than non-transfected cells and TEL/PDGFRbeta-transfected Ba/F3 cells. Decreased motile response was reversed by a 16-h treatment with STI571. A phosphoprotein-specific gel stain was used to identify TEL/PDGFRbeta and BCR/ABL-mediated changes in the phosphoproteome. These included changes on Crkl, Ras-GAP-binding protein 1, and for BCR/ABL, cytoskeletal proteins such as tubulin, and Nedd5. Decreased phosphorylation of Rho-GTPase dissociation inhibitor (Rho GDI) was also observed in BCR/ABL-transfected cells. This results in the activation of the Rho pathway, and treatment of cells with Y27632, an inhibitor of Rho kinase, inhibited DNA synthesis in BCR/ABL-transfected Ba/F3 cells but not TEL/PDGFRB-**expressing** cells. **Expression** of a dominant-negative RhoA inhibited both DNA synthesis and transwell migration, demonstrating the significance of this pathway in BCR/ABL-mediated transformation.

L10 ANSWER 8 OF 41 MEDLINE on STN

ACCESSION NUMBER: 2005313865 MEDLINE

DOCUMENT NUMBER: PubMed ID: 15890843

TITLE: Tubulin polyglutamylase enzymes are members of the TTL domain protein family.

AUTHOR: Janke Carsten; Rogowski Krzysztof; Wloga Dorota; Regnard Catherine; Kajava Andrey V; Strub Jean-Marc; Temurak Nevzat; van Dijk Juliette; Boucher Dominique; van Dorsselaer Alain; Suryavanshi Swati; Gaertig Jacek; Edde

Bernard
CORPORATE SOURCE: Centre de Recherches de Biochimie Macromoléculaire, CNRS,
34293 Montpellier, France.
SOURCE: Science, (2005 Jun 17) 308 (5729) 1758-62. Electronic
Publication: 2005-05-12.
Journal code: 0404511. ISSN: 1095-9203.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200506
ENTRY DATE: Entered STN: 20050618
Last Updated on STN: 20050701
Entered Medline: 20050630

AB Polyglutamylation of tubulin has been implicated in several functions of microtubules, but the identification of the responsible enzyme(s) has been challenging. We found that the neuronal tubulin polyglutamylase is a protein complex containing a tubulin tyrosine ligase-like (TLL) protein, TLL1. TLL1 is a member of a large family of proteins with a TTL homology domain, whose members could catalyze ligations of diverse amino acids to tubulins or other substrates. In the model protist *Tetrahymena thermophila*, two conserved types of polyglutamylases were characterized that differ in substrate preference and subcellular localization.

L10 ANSWER 9 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2005:412589 SCISEARCH

THE GENUINE ARTICLE: 914YX

TITLE: 3-Nitrotyrosine attenuates respiratory syncytial virus infection in human bronchial epithelial cell line

AUTHOR: Huang Y C T (Reprint); Li Z W; Brighton L E; Carson J L; Becker S; Soukup J M

CORPORATE SOURCE: CB 7315, 104 Mason Farm Rd, Chapel Hill, NC 27599 USA (Reprint); US EPA, Natl Hlth & Environm Effects Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA; Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA
huang.tony@epa.gov

COUNTRY OF AUTHOR: USA

SOURCE: AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, (MAY 2005) Vol. 288, No. 5, pp. L988-L996.
ISSN: 1040-0605.

PUBLISHER: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 55

ENTRY DATE: Entered STN: 28 Apr 2005

Last Updated on STN: 28 Apr 2005

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB 3-Nitrotyrosine (NO2Tyr), an L-tyrosine derivative during nitrative stress, can substitute the COOH-terminal tyrosine of alpha-tubulin, posttranslationally altering microtubular functions. Because infection of the cells by respiratory syncytial virus (RSV) may require intact microtubules, we tested the hypothesis that NO2Tyr would inhibit RSV infection and intracellular signaling via nitrotyrosination of alpha-tubulin. A human bronchial epithelial cell line (BEAS-2B) was incubated with RSV with or without NO2Tyr. The release of chemokines and viral particles and activation of interferon regulatory factor-3 (IRF-3) were measured. Incubation with NO2Tyr increased nitrotyrosinated alpha-tubulin, and NO2Tyr colocalized with microtubules. RSV-infected cells released viral particles, RANTES, and IL-8 in a time- and dose-dependent manner, and intracellular RSV proteins coprecipitated with alpha-tubulin. NO2Tyr attenuated the RSV-induced release of RANTES, IL-8, and viral particles by 50-90% and decreased alpha-tubulin-associated RSV proteins. 3-Chlorotyrosine, another L-tyrosine derivative, had no effects. NO2Tyr also inhibited the RSV-induced shift of the unphosphorylated form I of IRF-3 to the phosphorylated form II.

Pre-exposure of the cells to NO₂ (0.15 ppm, 4 h), which produced diffuse protein tyrosine nitration, did not affect RSV- induced release of RANTES, IL-8, or viral particles. NO₂Tyr did not affect the potential of viral spreading to the neighboring cells since the RSV titers were not decreased when the uninfected cells were cocultured with the preinfected cells in NO₂Tyr-containing medium. These results indicate that NO₂Tyr, by replacing the COOH-terminal tyrosine of alpha-tubulin, attenuated RSV infection, and the inhibition appeared to occur at the early stages of RSV infection.

L10 ANSWER 10 OF 41 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 2004637325 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15580622
TITLE: Differential **expression** of tyrosinated tubulin in
Spisula solidissima polar bodies.
AUTHOR: Alliegro Mark C; Alliegro Mary Anne
CORPORATE SOURCE: Marine Biological Laboratory, Woods Hole, Massachusetts,
and Department of Cell Biology, Louisiana State University
Health Sciences Center, New Orleans, Louisiana 70112, USA..
mallie@lshuhsc.edu
SOURCE: Developmental dynamics : an official publication of the
American Association of Anatomists, (2005 Jan) 232 (1)
216-20.
Journal code: 9201927. ISSN: 1058-8388.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200506
ENTRY DATE: Entered STN: 20041223
Last Updated on STN: 20050622
Entered Medline: 20050621

AB The C-terminus of alpha-tubulin can be reversibly modified by a specific **tyrosine ligase** to yield an isoform known as Tyr-tubulin. Tyr-tubulin is typically found in more dynamic microtubule arrays such as the mitotic spindle, as opposed to stable structures like centrioles and flagella. In developing systems, it is **expressed** in relatively undifferentiated, proliferative cell types but is replaced by detyrosinated (Glu-) tubulin during differentiation. We found Tyr-tubulin highly enriched in a single polar body of Spisula solidissima embryos. Quantitation of DNA content by Hoechst staining indicates that polar body 1 (with twice the DNA content of polar body 2) is the Tyr-tubulin-positive cell. Other than the apoptosis marker caspase, this is, to our knowledge, the first distinguishing marker antigen for polar bodies, particularly for one polar body vs. another. This localization of Tyr-tubulin is unlikely to be a byproduct of the meiotic process itself, because it arises after ejection of both polar bodies is complete. Although polar bodies are typically thought of as a terminally differentiated vestige of meiosis, the localization of this more dynamic tubulin isoform suggests an active role in early development.

L10 ANSWER 11 OF 41 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
DUPLICATE 3

ACCESSION NUMBER: 2004-07314 BIOTECHDS
TITLE: New testis-specific tubulin **tyrosine-ligase**
-like BGS-42 polypeptide, useful for preventing, treating or
ameliorating a medical condition, e.g. aberrant cellular
proliferation, reproductive disorders or testicular disorders

involving vector-mediated gene transfer,
expression in host cell for use in gene therapy
AUTHOR: FEDER J N; WU S; NELSON T C
PATENT ASSIGNEE: BRISTOL-MYERS SQUIBB CO
PATENT INFO: WO 2004005487 15 Jan 2004
APPLICATION INFO: WO 2003-US21605 9 Jul 2003
PRIORITY INFO: US 2002-394725 9 Jul 2002; US 2002-394725 9 Jul 2002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2004-099381 [10]

DERWENT ABSTRACT:

NOVELTY - A testis-specific tubulin tyrosine-ligase-like polypeptide, designated BGS-42 polypeptide, is new.

DETAILED DESCRIPTION - A testis-specific tubulin tyrosine-ligase-like polypeptide, designated BGS-42 polypeptide comprises or consists of: (a) a polypeptide fragment, domain, epitope or the full-length protein of a fully defined sequence of 541 amino acids (I), as given in the specification, or the encoded sequence included in ATCC Deposit Number PTA-4454, having tyrosine tubulin ligase activity; (b) a polypeptide comprising amino acids 2-541 of the sequence of (I), where the amino acids 2-541 comprises a polypeptide of (I) minus the start methionine; (c) a polypeptide comprising amino acids 1-541 or 73-365 of the sequence of (I); or (d) a polypeptide comprising at least 424 contiguous amino acids of the sequence of (I). **INDEPENDENT CLAIMS** are also included for: (1) an isolated nucleic acid molecule comprising or consisting of: (a) a polynucleotide fragment of 1838 bp (II), fully defined in the specification, or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II); (b) a polynucleotide encoding a polypeptide fragment, domain, epitope or the full-length protein of the sequence of (I), or a polypeptide fragment, domain or epitope encoded by the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II), having tyrosine tubulin ligase activity; (c) a polynucleotide which is a variant or an allelic variant of (II); (d) nucleotides 156-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 2-541 of (I) minus the start methionine; (e) nucleotides 153-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 1-541 of (I) including the start codon; (f) nucleotides 369-1247 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 73-365 of (I); (g) a polynucleotide that encodes at least 424 contiguous amino acids of (I); (h) at least 1272 contiguous nucleotides of (II); (i) a polynucleotide which represents the complementary sequence (antisense) of (II); (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides above, where the polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A or only T residues; (k) a polynucleotide comprising or consisting of the BGS-42 gene or BGS-42 promoter; or (l) a nucleotide sequence of 2241 bp, fully defined in the specification; (2) a recombinant vector comprising the isolated nucleic acid molecule; (3) an isolated antibody that binds specifically to BGS-42 polypeptide; (4) a recombinant host cell comprising the vector sequences, or expressing the BGS-42 polypeptide; (5) making an isolated polypeptide; (6) preventing, treating or ameliorating a medical condition; and (7) diagnosing a pathological condition or a susceptibility to a pathological condition in a subject.

WIDER DISCLOSURE - Also disclosed are screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides, and methods of controlling the expression of the polypeptide.

BIOTECHNOLOGY - Preparation (claimed): The BGS-42 polypeptide is prepared by standard recombinant methods. Making an isolated polypeptide comprises culturing the recombinant host cell under conditions such that the polypeptide is expressed, and recovering the polypeptide. Preferred Polypeptide: The full-length protein comprises sequential amino acid deletions from the C-terminus or the N-terminus. Preferred Nucleic Acid: The polynucleotide fragment consists of a nucleotide sequence encoding a human tyrosine tubulin ligase. Preferred Method: Preventing, treating or ameliorating a medical condition comprises administering to a mammalian subject a therapeutic amount of the BGS-42 polypeptide or its modulator. Diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprises determining the presence or absence of a mutation in the polynucleotide cited above, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation. Alternatively, the method comprises determining the presence or amount of expression of the BGS-42 polypeptide in a tyrosine tubulin ligase sample, and diagnosing a pathological

condition or a susceptibility to a pathological condition based on the presence or amount of **expression** of the polypeptide.

ACTIVITY - Cytostatic; Respiratory-Gen.; Gastrointestinal-Gen.; Neuroprotective; Endocrine-Gen.; Antiinflammatory; Anabolic; Hypertensive; Osteopathic; Nootropic; Antiparkinsonian; Antiarthritic; Antiasthmatic; Anti-HIV; Antibacterial; Immunosuppressive; Antiseborrheic; Dermatological. No biological data given.

MECHANISM OF ACTION - Tyrosine Ligase Modulator; Gene Therapy. No biological data given.

USE - The BGS-42 polypeptide or polynucleotide can be used for diagnosing a pathological condition or a susceptibility to a pathological condition in a subject, and for preventing, treating or ameliorating a medical condition, such as a disorder related to aberrant tubulin ligase activity, a disorder related to aberrant tubulin-carboxypeptidase activity, aberrant cellular proliferation, reproductive disorders, testicular disorders, testicular cancer, pulmonary disorders, lung cancer, gastrointestinal disorders, colon cancer, stomach cancer, neural disorders, brain cancer, liver cancer, or proliferative condition of the testis, lung, small intestine, brain or lymph tissue (all claimed). The BGS-42 polypeptide, polynucleotide, or their modulators are also useful for treating infertility, Cushing's syndrome, emphysema, pneumonia, Addison's disease, acromegaly, Alzheimer's disease, or Parkinson's disease. The BGS-42 polypeptide can be used as a preventive agent for immunological disorders including arthritis, asthma, AIDS, sepsis, acne, Sjogren's disease or scleroderma. The antibodies may be used to purify, detect and target the BGS-42 polypeptides.

ADMINISTRATION - Administration of the antibody is 0.1-100 (preferably 1-10) mg/kg, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, intranasally, epidurally, intraventricularly, intrathecally, topically, orally, or rectally.

EXAMPLE - A polynucleotide encoding a BGS-42 polypeptide was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence to synthesize insertion fragments. The pQE-9 vector was digested with BamHI and XbaI and the amplified fragment was ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial ribosome-binding site. The ligation mixture was used to transform Escherichia coli strain M15/rep4. Transformants were identified by their ability to grow on LB (Luria bertani) plates, and ampicillin/kanamycin-resistant colonies were selected. Clones containing the desired constructs were grown overnight in liquid culture, i.e. LB media, supplemented with both ampicillin and kanamycin. Isopropyl-B-D-thiogalacto pyranoside (IPTG) was added to induce gene **expression**. Cells were grown for an extra 3-4 hours, and cells were harvested by centrifugation. The cell pellet obtained by centrifugation was solubilized, and the solubilized BGS-42 protein was purified using a metal chelating column under conditions that allow tight binding of the protein. (343 pages)

L10 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2005:156681 HCAPLUS
Correction of: 2005:60757

DOCUMENT NUMBER: 142:216629
Correction of: 142:132329

TITLE: Gene **expression** profiles and biomarkers for the detection of hyperlipidemia and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004248170	A1	20041209	US 2004-812777	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330

PRIORITY APPLN. INFO.:

US 1999-115125P	P	19990106
US 2000-477148	B1	20000104
US 2002-268730	A2	20021009
US 2003-601518	A2	20030620
US 2004-802875	A2	20040312
US 2004-812777	A	20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular hyperlipidemia, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L10 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:824055 HCAPLUS

DOCUMENT NUMBER: 141:330185

TITLE: Gene expression profiling for diagnosis and treatment of angiogenesis-related disorders

INVENTOR(S): Gonda, Thomas John; Kremmidiotis, Gabriel

PATENT ASSIGNEE(S): Bionomics Limited, Australia

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085675	A1	20041007	WO 2004-AU383	20040326
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: AU 2003-901511 A 20030328

AB The present invention provides methods of gene expression profiling for diagnosis and treatment of angiogenesis-related disorders. Diseases of the invention include cancer, rheumatoid arthritis, diabetic retinopathy, psoriasis, cardiovascular diseases such as atherosclerosis, ischemic limb disease and coronary heart disease.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:1997 HCAPLUS
 DOCUMENT NUMBER: 142:111841
 TITLE: Gene **expression** profiles and biomarkers for the detection of depression-related and other disease-related gene transcripts in blood
 INVENTOR(S): Liew, Choong-Chin
 PATENT ASSIGNEE(S): Chondrogene Limited, Can.
 SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. No. 802,875.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 47
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265868	A1	20041230	US 2004-812702	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2004265868	A1	20041230	US 2004-812702	20040330
US 2004265868	A1	20041230	US 2004-812702	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812702	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular mental depression, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

ACCESSION NUMBER: 2005:60760 HCAPLUS
 Correction of: 2004:1036573
 DOCUMENT NUMBER: 142:153477
 Correction of: 142:16776
 TITLE: Gene **expression** profiles and biomarkers for the detection of Chagas disease and other disease-related gene transcripts in blood
 INVENTOR(S): Liew, Choong-Chin
 PATENT ASSIGNEE(S): Chondrogene Limited, Can.
 SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. No. 802,875.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 47
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2004241729	A1	20041202	US 2004-813097	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241729	A1	20041202	US 2004-813097	20040330
US 2004241729	A1	20041202	US 2004-813097	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330

PRIORITY APPLN. INFO.:

US 1999-115125P	P	19990106
US 2000-477148	B1	20000104
US 2002-268730	A2	20021009
US 2003-601518	A2	20030620
US 2004-802875	A2	20040312
US 2004-813097	A	20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular Chagas disease, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L10 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:60759 HCAPLUS
Correction of: 2004:1036572
DOCUMENT NUMBER: 142:111840
Correction of: 142:16824

TITLE: Gene expression profiles and biomarkers for the detection of lung disease-related and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin
PATENT ASSIGNEE(S): ChondroGene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 47
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330

PRIORITY APPLN. INFO.:

US 1999-115125P	P	19990106
US 2000-477148	B1	20000104
US 2002-268730	A2	20021009

US 2003-601518 A2 20030620
US 2004-802875 A2 20040312
US 2004-812764 A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L10 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:60754 HCAPLUS
Correction of: 2004:1036571

DOCUMENT NUMBER: 142:233342
Correction of: 142:16836

TITLE: Sequences of human schizophrenia related genes and use for diagnosis, prognosis and therapy

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE:

LANGUAGE: Patent
English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330
US 2005208519	A1	20050922	US 2004-989191	20041115

PRIORITY APPLN. INFO.:

US 1999-115125P	P	19990106
US 2000-477148	B1	20000104
US 2002-268730	A2	20021009
US 2003-601518	A2	20030620
US 2004-802875	A2	20040312
US 2004-812731	A	20040330
WO 2004-US20836	A2	20040621

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L10 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:60755 HCAPLUS

Correction of: 2004:1036570
DOCUMENT NUMBER: 142:154259
Correction of: 142:36938
TITLE: Analysis of genetic information contained in peripheral blood for diagnosis, prognosis and monitoring treatment of allergy, infection and genetic disease in human
INVENTOR(S): Liew, Choong-Chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 47
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004265869	A1	20041230	US 2004-812716	20040330

PRIORITY APPLN. INFO.:
US 1999-115125P P 19990106
US 2000-477148 B1 20000104
US 2002-268730 A2 20021009
US 2003-601518 A2 20030620
US 2004-802875 A2 20040312
US 2004-812707 A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular allergy, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L10 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:722839 HCAPLUS
DOCUMENT NUMBER: 141:238811
TITLE: Protein and cDNA sequences of a novel human testis-specific tubulin tyrosine ligase like protein BGS-42, and diagnostic and therapeutic use
INVENTOR(S): Feder, John N.; Nelson, Thomas C.; Wu, Shujian; Krystek, Stanley R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 199 pp., Cont.-in-part of U.S. Ser. No. 615,659.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004171131	A1	20040902	US 2003-635977	20030807
US 2004157234	A1	20040812	US 2003-615659	20030709
PRIORITY APPLN. INFO.:			US 2002-394725P	P 20020709
			US 2003-615659	A2 20030709

AB The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L10 ANSWER 20 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:405282 SCISEARCH

THE GENUINE ARTICLE: 812TJ

TITLE: Suppression of nuclear oscillations in *Saccharomyces cerevisiae* expressing Glu tubulin

AUTHOR: Badin-Larcon A C; Boscheron C (Reprint); Soleilhac J M; Piel M; Mann C; Denarier E; Fourest-Lieuvin A; Lafanechere L; Bornens M; Job D

CORPORATE SOURCE: CEA Grenoble, DRDC, Lab Cytosquelette, INSERM, U366, 17 Rue Martyrs, F-38054 Grenoble, France (Reprint); CEA Grenoble, DRDC, Lab Cytosquelette, INSERM, U366, F-38054 Grenoble, France; Inst Curie, Sect Rech, CNRS, UMR 144, F-75248 Paris 05, France; CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France

COUNTRY OF AUTHOR: France

SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (13 APR 2004) Vol. 101, No. 15, pp. 5577-5582.

ISSN: 0027-8424.

PUBLISHER: NATL ACAD SCIENCES, 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 37

ENTRY DATE: Entered STN: 14 May 2004

Last Updated on STN: 14 May 2004

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB In most eukaryotic cells, the C-terminal amino acid of alpha-tubulin is aromatic (Tyr in mammals and Phe in *Saccharomyces cerevisiae*) and is preceded by two glutamate residues. In mammals, the C-terminal Tyr of alpha-tubulin is subject to cyclic removal from the peptide chain by a carboxypeptidase and readdition to the chain by a tubulin-Tyr ligase. There is evidence that tubulin-Tyr ligase suppression and the resulting accumulation of detyrosinated (Glu) tubulin favor tumor growth, both in animal models and in human cancers. However, the molecular basis for this apparent stimulatory effect of Glu tubulin accumulation on tumor progression is unknown. Here we have developed *S. cerevisiae* strains expressing only Glu tubulin and used them as a model to assess the consequences of Glu tubulin accumulation in cells. We find that Glu tubulin strains show defects in nuclear oscillations. These defects are linked to a markedly decreased association of the yeast ortholog of CLIP170, Bik1p, with microtubule plus-ends. These results indicate that the accumulation of Glu tubulin in cells affects microtubule tip complexes that are important for microtubule interactions with the cell cortex.

L10 ANSWER 21 OF 41 MEDLINE on STN

DUPLICATE 5

ACCESSION NUMBER: 2004470309 MEDLINE

DOCUMENT NUMBER: PubMed ID: 15382060

TITLE: Low **expression** of human tubulin tyrosine
ligase and suppressed tubulin
tyrosination/detyrosination cycle are associated with
impaired neuronal differentiation in neuroblastomas with
poor prognosis.

AUTHOR: Kato Chiaki; Miyazaki Kou; Nakagawa Atsuko; Ohira Miki;
Nakamura Yohko; Ozaki Toshinori; Imai Toshio; Nakagawara
Akira

CORPORATE SOURCE: Division of Biochemistry, Chiba Cancer Center Research
Institute, Chiba, Japan.

SOURCE: International journal of cancer. Journal international du
cancer, (2004 Nov 10) 112 (3) 365-75.
Journal code: 0042124. ISSN: 0020-7136.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200412

ENTRY DATE: Entered STN: 20040922
Last Updated on STN: 20041219
Entered Medline: 20041202

AB Neuroblastoma (NBL), one of the most common childhood solid tumors, has a
distinct nature in different prognostic subgroups. However, the precise
mechanism underlying this phenomenon remains largely unknown. To
understand the molecular and genetic bases of neuroblastoma, we have
generated its cDNA libraries and identified a human ortholog of tubulin
tyrosine ligase gene (hTTL/Nbla0660) as a differentially
expressed gene at high levels in a favorable subset of the tumor.
Tubulin is subjected to several types of evolutionarily conserved
posttranslational modification, including tyrosination and detyrosination.
Tubulin **tyrosine ligase** catalyzes ligation of the
tyrosine residue to the COOH terminus of the detyrosinated form of
alpha-tubulin. The measurement of hTTL mRNA **expression** in 74
primary neuroblastomas by quantitative real-time reverse transcription-PCR
revealed that its high **expression** was significantly associated
with favorable stages (1, 2 and 4s; $p = 0.0069$), high TrkA
expression ($p = 0.002$), a single copy of MYCN ($p < 0.00005$),
tumors found by mass screening ($p = 0.0042$), nonadrenal origin ($p =$
 0.0042) and good prognosis ($p = 0.023$). The log-rank test showed that
high **expression** of hTTL was an indicator of favorable prognosis
($p = 0.026$). Immunohistochemical analysis using specific antibodies
generated by us demonstrated that tyrosinated tubulin (Tyr-tubulin),
detyrosinated tubulin (Glu-tubulin) and hTTL as well as Delta2-tubulin
were positive in favorable tumors, whereas only Delta2-tubulin was
positive in the tumors with MYCN amplification. In an RTBM1 neuroblastoma
cell line, hTTL was increased after treating the cells with bone
morphogenetic protein 2 (BMP2) or all-trans retinoic acid (RA), which
induced neuronal differentiation. These results suggest that the
deregulated tubulin tyrosination/detyrosination cycle caused by decreased
expression of hTTL is associated with inhibition of neuronal
differentiation and enhancement of cell growth in the primary
neuroblastomas with poor outcome.

L10 ANSWER 22 OF 41 EMBASE COPYRIGHT (c) 2005 Elsevier B.V. All rights
reserved on STN

ACCESSION NUMBER: 2004018647 EMBASE

TITLE: Endophyte-Infected Tall Fescue Diet Alters Gene
Expression in Heifer Luteal Tissue as Revealed by
Interspecies Microarray Analysis.

AUTHOR: Jones K.L.; King S.S.; Iqbal M.J.

CORPORATE SOURCE: K.L. Jones, Dept. of Anim. Sci., Food and Nutr., S.
Illinois University Carbondale, MC 4417, 1205 Lincoln
Drive, Carbondale, IL 62901, United States. kljones@siu.edu

SOURCE: Molecular Reproduction and Development, (2004) Vol. 67, No.
2, pp. 154-161.
Refs: 66
ISSN: 1040-452X CODEN: MREDEE

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 004 Microbiology
021 Developmental Biology and Teratology
052 Toxicology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20040129
Last Updated on STN: 20040129

AB Cattle consuming endophyte-infected tall fescue grass have an associated reduction in circulating progesterone and reduced reproductive rates. In this study, commercially available rat microarrays were used to analyze the gene expression in luteal tissues from heifers fed endophyte-free fescue, endophyte-infected fescue, or endophyte-infected fescue supplemented with the dopamine (DA) antagonist, domperidone. The number of hybridized spots represented approximately 40% of the total 10,000 rat genes/ESTs evaluated. Each luteal sample was analyzed in triplicate, resulting in within treatment correlation coefficients of ≥ 0.98 . Median values of mRNA abundance from luteal tissue taken from the endophyte-infected fed heifers revealed 598 genes and ESTs that were down regulated and 56 genes and ESTs that were upregulated compared with luteal mRNA values from the endophyte-free treatment. There were fewer comparative differences between median values from luteal mRNA from the endophyte-free versus feeding endophyte-infected plus domperidone treated heifers. Only 19 genes and ESTs were upregulated and two were down-regulated. .COPYRG. 2004 Wiley-Liss, Inc.

L10 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:737915 HCAPLUS

DOCUMENT NUMBER: 139:256359

TITLE: Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses

INVENTOR(S): Zerhusen, Bryan D.; Patturajan, Meera; Kekuda, Ramesh; Miller, Charles E.; Rieger, Daniel K.; Pena, Carol E. A.; Shimkets, Richard A.; Li, Li; Berghs, Constance; Zhong, Mei; Casman, Stacie J.; Voss, Edward Z.; Boldog, Ferenc L.; Padigaru, Muralidhara; Smithson, Glennnda; Shenoy, Suresh G.; Ji, Weizhen; Gorman, Linda; Vernet, Corine A. M.; Leite, Mario W.; Guo, Xiaojia; Anderson, David W.; Spytek, Kimberly A.; Gerlach, Valerie L.; Burgess, Catherine E.; Khramtsov, Nikolai V.; Ort, Tatiana; Ellerman, Karen; Rastelli, Luca; Agee, Michele L.; Chaudhuri, Amitabha; Chant, John S.; Dipippo, Vincent A.; Edinger, Shlomit; Eisen, Andrew; Gangolli, Esha A.; Giot, Loic; Ooi, Chean Eng; Rothenberg, Mark E.; Spaderna, Steven K.; Hjalt, Tord; Liu, Xiaohong; Taupier, Raymond J., Jr.; Catterton, Elina

PATENT ASSIGNEE(S): Curagen Corporation, USA

SOURCE: PCT Int. Appl., 562 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 159

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076642	A2	20030918	WO 2002-US24459	20020802
WO 2003076642	A3	20041014		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004014053	A1	20040122	US 2002-210130	20020801

CA 2449341	AA	20030918	CA 2002-2449341	20020802
EP 1492807	A2	20050105	EP 2002-806720	20020802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI, CY, TR, BG, CZ, EE, SK				
JP 2005526507	T2	20050908	JP 2003-574839	20020802
PRIORITY APPLN. INFO.:				
			US 2001-309501P	P 20010802
			US 2001-310291P	P 20010803
			US 2001-310951P	P 20010808
			US 2001-311292P	P 20010809
			US 2001-311979P	P 20010813
			US 2001-312203P	P 20010814
			US 2001-313156P	P 20010817
			US 2001-313201P	P 20010817
			US 2001-313702P	P 20010820
			US 2001-314031P	P 20010821
			US 2001-314466P	P 20010823
			US 2001-315403P	P 20010828
			US 2001-315853P	P 20010829
			US 2001-316508P	P 20010831
			US 2001-323936P	P 20010921
			US 2001-338078P	P 20011203
			US 2002-354655P	P 20020205
			US 2002-361764P	P 20020305
			US 2002-373825P	P 20020419
			US 2002-380971P	P 20020515
			US 2002-380980P	P 20020515
			US 2002-381039P	P 20020516
			US 2002-383761P	P 20020528
			US 2002-383887P	P 20020529
			US 2002-210130	A2 20020801
			US 2001-313643P	P 20010820
			US 2001-322716P	P 20010917
			WO 2002-US24459	W 20020802

AB Disclosed herein are 49 cDNA sequences that encode novel human polypeptides that are members of various protein families. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

L10 ANSWER 24 OF 41 MEDLINE on STN DUPLICATE 6
 ACCESSION NUMBER: 2003493733 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 14571137
 TITLE: Cloning and genomic organization of the TTL gene on mouse chromosome 2 and human chromosome 2q13.
 AUTHOR: Erck C; MacLeod R A F; Wehland J
 CORPORATE SOURCE: Department of Cell Biology, German Research Center of Biotechnology, Braunschweig, Germany.. cer@gbf.de
 SOURCE: Cytogenetic and genome research, (2003) 101 (1) 47-53. Journal code: 101142708. ISSN: 1424-859X.
 PUB. COUNTRY: Switzerland
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200403
 ENTRY DATE: Entered STN: 20031023
 Last Updated on STN: 20040316
 Entered Medline: 20040315

AB Tubulin tyrosine ligase (TTL) is a cytosolic enzyme involved in the posttranslational modification of tubulin. In the assembled form microtubules are detyrosinated over time at the C-terminus of alpha-tubulin. After microtubular disassembly TTL restores tyrosine residues back to the detyrosinated tubulin leading to a cycle of detyrosination/tyrosination. Here we report the isolation of the human and mouse TTL cDNA. In comparison with other known TTL sequences, namely bovine, rat and porcine, we found that only porcine TTL deviates in length

by having an insertion of two glutamate residues. In mouse and human TTL the genomic coding sequence is composed of seven exons with normal intron/exon boundaries. Using fluorescence in situ hybridization (FISH), we mapped the murine TTL gene to mouse chromosome 2 (MMU2). Human TTL has been located to chromosome 2q13 (HSA2q13). In addition, we found frequently truncated PCR products of hTTL transcripts with aberrant splicing in tumors.

Copyright 2003 S. Karger AG, Basel

L10 ANSWER 25 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:56685 SCISEARCH

THE GENUINE ARTICLE: 630QF

TITLE: Identification of CfNek, a novel member of the NIMA family of cell cycle regulators, as a polypeptide copurifying with tubulin polyglutamylase activity in Crithidia

AUTHOR: Westermann S; Weber K (Reprint)

CORPORATE SOURCE: Max Planck Inst Biophys Chem, Dept Biochem, Fassberg 11, D-37077 Gottingen, Germany (Reprint); Max Planck Inst Biophys Chem, Dept Biochem, D-37077 Gottingen, Germany

COUNTRY OF AUTHOR: Germany

SOURCE: JOURNAL OF CELL SCIENCE, (15 DEC 2002) Vol. 115, No. 24, pp. 5003-5012.

ISSN: 0021-9533.

PUBLISHER: COMPANY OF BIOLOGISTS LTD, BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 48

ENTRY DATE: Entered STN: 24 Jan 2003

Last Updated on STN: 24 Jan 2003

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Post-translational glutamylation of tubulin plays an important role in regulating the interaction between microtubules and associated proteins, but so far the enzymes involved in this process have not been cloned from any cellular source. Using a modified purification scheme that employs a hydroxyapatite chromatography as the final step we identified a 54 kDa band as the major polypeptide copurifying with tubulin polyglutamylase activity from the trypanosomatid Crithidia fasciculata. Based on peptide sequence information we have cloned the corresponding cDNA and identify Crithidia p54 as a novel member (termed CfNek) of the NIMA family of putative cell cycle regulators. CfNek is a protein of 479 amino acids that contains an unusual protein kinase domain that lacks the glycine-rich loop in subdomain I. The protein also harbours a PEST sequence and a pleckstrin homology domain. The tubulin polyglutamylase preparation displays the P-casein phosphorylation activity typical for NIMA related kinases. Recombinant His-tagged CfNek expressed in Crithidia localises to the flagellar attachment zone/basal body of the parasite. After purification on a Ni²⁺-column the recombinant enzyme preparation displays ATP-dependent tubulin polyglutamylase activity as well as casein-phosphorylation activity.

L10 ANSWER 26 OF 41 MEDLINE on STN DUPLICATE 7

ACCESSION NUMBER: 2003006942 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12512949

TITLE: Cloning of rat olfactory bulb tubulin tyrosine ligase cDNA: a dominant negative mutant and an antisense cDNA increase the proliferation rate of cells in culture.

AUTHOR: Mas Carlos R; Arregui Carlos O; Filiberti Adrian; Argarana Carlos E; Barra Hector S

CORPORATE SOURCE: Centro de Investigaciones en Quimica Biologica de Cordoba, CIQUIBIC (UNC-CONICET), Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Cordoba, Argentina.

SOURCE: Neurochemical research, (2002 Nov) 27 (11) 1453-8. Journal code: 7613461. ISSN: 0364-3190.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200303
ENTRY DATE: Entered STN: 20030107
Last Updated on STN: 20030308
Entered Medline: 20030307

AB In this paper we describe the cloning of rat olfactory bulb tubulin tyrosine ligase (TTL) cDNA, and investigate the physiological role of TTL in cultured CHO-K1 cells. Comparison of the deduced amino acid sequence of rat TTL cDNA with those of bovine and pig showed approximately 90% of identity. Transient transfection of CHO-K1 cells with a dominant negative mutant of TTL that contains the binding site to the substrate (tubulin) but not the catalytic domain, significantly decreased the endogenous TTL activity as determined in vitro. Similar results were obtained using a construction encoding for the antisense sequence of TTL. The reduction in TTL activity is not accompanied by a decrease in the tyrosination levels of microtubules, as judged by immunofluorescence analysis. Strikingly, the number of cells in the plates transfected with the mutant TTL or the antisense TTL cDNA was, after 72 h of culture, two and three times higher, respectively, than the number of cells in the control plates. These results support the hypothesis that TTL may play a role in the regulation of the cell cycle in living cells.

L10 ANSWER 27 OF 41 MEDLINE on STN DUPLICATE 8
ACCESSION NUMBER: 2001013397 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11004583
TITLE: Incorporation of nitrotyrosine into alpha-tubulin by recombinant mammalian tubulin-tyrosine ligase.
AUTHOR: Kalisz H M; Erck C; Plessmann U; Wehland J
CORPORATE SOURCE: Gesellschaft fur Biotechnologische Forschung, Abteilung Zellbiologie, Braunschweig, Germany.
SOURCE: Biochimica et biophysica acta, (2000 Aug 31) 1481 (1) 131-8.
Journal code: 0217513. ISSN: 0006-3002.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200011
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001102

AB Tubulin-tyrosine ligase (TTL, EC 6.3.2.25) from porcine brain, which catalyses the readdition of tyrosine to the C-terminus of detyrosinated alpha-tubulin, was cloned and expressed in Escherichia coli as a glutathione S-transferase-fusion protein. Upon cleavage of the immobilised fusion protein, an electrophoretically homogeneous enzyme was obtained. Recombinant TTL, which exhibited similar catalytic properties as the mammalian enzyme purified from brain tissue, was capable of using nitrotyrosine as an alternative substrate in vitro. Incorporation of tyrosine into tubulin was competitively inhibited by nitrotyrosine with an apparent K(i) of 0.24 mM. The TTL-catalysed incorporation of nitrotyrosine as sole substrate into alpha-tubulin was clearly detectable at concentrations of 10 microM by immunological methods using nitrotyrosine specific antibodies. However, in competition with tyrosine 20-fold higher concentrations of nitrotyrosine were necessary before its incorporation became evident. Analysis of the C-terminal peptides of in vitro modified alpha-tubulin by MALDI-MS confirmed the covalent incorporation of nitrotyrosine into tubulin by TTL. In contrast to the C-terminal tyrosine, pancreatic carboxypeptidase A was incapable of cleaving nitrotyrosine from the modified alpha-tubulin.

L10 ANSWER 28 OF 41 MEDLINE on STN DUPLICATE 9
ACCESSION NUMBER: 2001070000 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11054573
TITLE: Characterization of the human tubulin tyrosine

AUTHOR: ligase-like 1 gene (TTLL1) mapping to 22q13.1.
 CORPORATE SOURCE: Trichet V; Ruault M; Roizes G; De Sario A
 Sequences Repetees et Centromeres Humains, CNRS UPR 1142,
 Institut de Biologie, 4, bv Henri IV, 34060, Montpellier,
 France.
 SOURCE: Gene, (2000 Oct 17) 257 (1) 109-17.
 Journal code: 7706761. ISSN: 0378-1119.
 PUB. COUNTRY: Netherlands
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 OTHER SOURCE: GENBANK-AF104927; GENBANK-AF173935
 ENTRY MONTH: 200101
 ENTRY DATE: Entered STN: 20010322
 Last Updated on STN: 20010322
 Entered Medline: 20010104

AB This paper reports the characterization of the human tubulin
 tyrosine ligase-like 1 gene (TTLL1), which maps to the
 chromosome region 22q13.1 and has been partially duplicated on three other
 acrocentric chromosomes: 13, 15 and 21. We describe the complete cDNA,
 TTLL1a, coding for the putative 423 amino acid long TTLL1 and alternative
 transcripts coding for truncated TTLL1. Likely TTLL1a corresponds to the
 1.8 kb transcript that was detected in a wide range of tissues and has a
 stronger expression in heart, brain and testis. A 4.8 kb
 transcript was found only in brain tissues. We present an interspecies
 sequence comparison, revealing three conserved domains, named TTLD1, TTLD2
 and TTLD3, that are specific to the TTLs and TTL-like proteins.

L10 ANSWER 29 OF 41 MEDLINE on STN
 ACCESSION NUMBER: 2000148025 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 10685598
 TITLE: Tubulin-tyrosine ligase, a long-lasting
 enigma.
 AUTHOR: Erck C; Frank R; Wehland J
 CORPORATE SOURCE: Abteilung Zellbiologie, Gesellschaft fuer Biotechnologische
 Forschung, Braunschweig, Germany.
 SOURCE: Neurochemical research, (2000 Jan) 25 (1) 5-10. Ref: 48
 Journal code: 7613461. ISSN: 0364-3190.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200003
 ENTRY DATE: Entered STN: 20000320
 Last Updated on STN: 20000320
 Entered Medline: 20000309

AB Tubulins and microtubules are subjected to several post-translational
 modifications of which the reversible detyrosination/tyrosination of the
 carboxy-terminal end of most alpha-tubulins has been extensively analysed.
 This modification cycle involves a specific carboxypeptidase and the
 activity of the tubulin-tyrosine ligase (TTL). The
 true physiological function of TTL has so far not been established. This
 review describes the purification of TTL to homogeneity by biochemical
 methods, its in vitro properties and the generation of monoclonal
 antibodies. These mabs not only enabled a very convenient and rapid
 purification of TTL by immunoaffinity chromatography but also its
 extensive characterization by protein sequencing, which led to the
 isolation of the full length cDNA. With this information, gene disruption
 should be feasible in order to determine the physiological significance of
 the tyrosination cycle.

L10 ANSWER 30 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on
 STN
 ACCESSION NUMBER: 2000:434745 SCISEARCH
 THE GENUINE ARTICLE: 321LD
 TITLE: Phosphorylation of tubulin tyrosine
 ligase: A potential mechanism for regulation of

alpha-tubulin tyrosination
 AUTHOR: Idriss H T (Reprint)
 CORPORATE SOURCE: Univ St Andrews, Sch Biomed Sci, N Haugh, St Andrews KY16 9ST, Fife, Scotland (Reprint); Univ St Andrews, Ctr Biomed Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77550 USA
 COUNTRY OF AUTHOR: Scotland; USA
 SOURCE: CELL MOTILITY AND THE CYTOSKELETON, (MAY 2000) Vol. 46, No. 1, pp. 1-5.
 ISSN: 0886-1544.
 PUBLISHER: WILEY-LISS, DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA.
 DOCUMENT TYPE: General Review; Journal
 LANGUAGE: English
 REFERENCE COUNT: 28
 ENTRY DATE: Entered STN: 2000
 Last Updated on STN: 2000

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The tubulin tyrosination/detyrosination cycle is a well-established posttranslational modification, which is carried out by two enzymes: Tubulin Tyrosine Ligase (TTL) and Tubulin Tyrosine Carboxypeptidase (TTCP). In this paper, I present evidence suggesting that the cycle itself is under the hierarchical control of reversible phosphorylation and that PKC mediated phosphorylation of TTL inhibits its activity, thereby preventing tubulin tyrosination. Phosphorylation of TTL is predicted to occur in a postulated Mg⁺⁺/ATP binding fold, leading to inhibition of Mg⁺⁺/ATP binding and TTL mediated catalysis. The implications of such control are also discussed. (C) 2000 Wiley-Liss, Inc.

L10 ANSWER 31 OF 41 MEDLINE on STN DUPLICATE 10
 ACCESSION NUMBER: 1998070560 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 9405300
 TITLE: Suppression of tubulin tyrosine ligase during tumor growth.
 AUTHOR: Lafanechere L; Courtay-Cahen C; Kawakami T; Jacrot M; Rudiger M; Wehland J; Job D; Margolis R L
 CORPORATE SOURCE: Laboratoire du Cytosquelette, INSERM U366, DBMS, Commissariat a l'Energie Atomique/Grenoble, Grenoble, France.
 SOURCE: Journal of cell science, (1998 Jan) 111 (Pt 2) 171-81.
 Journal code: 0052457. ISSN: 0021-9533.
 PUB. COUNTRY: ENGLAND: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199803
 ENTRY DATE: Entered STN: 19980326
 Last Updated on STN: 19980326
 Entered Medline: 19980317

AB The C terminus of the tubulin alpha-subunit of most eukaryotic cells undergoes a cycle of tyrosination and detyrosination using two specific enzymes, a tubulin tyrosine ligase (TTL) and a tubulin carboxypeptidase. Although this enzyme cycle is conserved in evolution and exhibits rapid turnover, the meaning of this modification has remained elusive. We have isolated several NIH-3T3 derived clonal cell lines that lack TTL (TTL⁻). TTL⁻ cells contain a unique tubulin isotype (delta2-tubulin) that can be detected with specific antibodies. When injected into nude mice, both TTL⁻ cells and TTL⁻ cells stably transfected with TTL cDNA form sarcomas. But in tumors formed from TTL rescued cells, TTL is systematically lost during tumor growth. A strong selection process has thus acted during tumor growth to suppress TTL activity. In accord with this result, we find suppression of TTL activity in the majority of human tumors assayed with delta2-tubulin antibody. We conclude there is a widespread loss of TTL activity during tumor growth in situ, suggesting that TTL activity may play a role in tumor cell regulation.

L10 ANSWER 32 OF 41 MEDLINE on STN DUPLICATE 11
 ACCESSION NUMBER: 97234553 MEDLINE

DOCUMENT NUMBER: PubMed ID: 9118990
 TITLE: Tubulin post-translational modifications--enzymes and their mechanisms of action.
 AUTHOR: MacRae T H
 CORPORATE SOURCE: Department of Biology, Dalhousie University, Halifax, Canada.
 SOURCE: European journal of biochemistry / FEBS, (1997 Mar 1) 244 (2) 265-78. Ref: 172
 Journal code: 0107600. ISSN: 0014-2956.
 PUB. COUNTRY: GERMANY: Germany, Federal Republic of
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199704
 ENTRY DATE: Entered STN: 19970506
 Last Updated on STN: 20000303
 Entered Medline: 19970422

AB This review describes the enzymes responsible for the post-translational modifications of tubulin, including detyrosination/tyrosination, acetylation/deacetylation, phosphorylation, polyglutamylolation, polyglycylation and the generation of non-tyrosinatable alpha-tubulin. Tubulin tyrosine-ligase, which reattaches tyrosine to detyrosinated tubulin, has been extensively characterized and its gene sequenced. Enzymes such as tubulin-specific carboxypeptidase and alpha-tubulin acetyltransferase, required, respectively, for detyrosination and acetylation of tubulin, have yet to be purified to homogeneity and examined in defined systems. This has produced some conflicting results, especially for the carboxypeptidase. The phosphorylation of tubulin by several different types of kinases has been studied in detail but drawing conclusions is difficult because many of these enzymes modify proteins other than their actual substrates, an especially pertinent consideration for in vitro experiments. Tubulin phosphorylation in cultured neuronal cells has proven to be the best model for evaluation of kinase effects on tubulin/microtubule function. There is little information on the enzymes required for polyglutamylolation, polyglycylation, and production of non-tyrosinatable tubulin, but the available data permit interesting speculation of a mechanistic nature. Clearly, to achieve a full appreciation of tubulin post-translational changes the responsible enzymes must be characterized. Knowing when the enzymes are active in cells, if soluble or polymerized tubulin is the preferred substrate and the amino acid residues modified by each enzyme are all important. Moreover, acquisition of purified enzymes will lead to cloning and sequencing of their genes. With this information, one can manipulate cell genomes in order to either modify key enzymes or change their relative amounts, and perhaps reveal the physiological significance of tubulin post-translational modifications.

L10 ANSWER 33 OF 41 MEDLINE on STN DUPLICATE 12
 ACCESSION NUMBER: 97261916 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 9108330
 TITLE: Tubulin tyrosine ligase: protein and mRNA expression in developing rat skeletal muscle.
 AUTHOR: Arregui C O; Mas C R; Argarana C E; Barra H S
 CORPORATE SOURCE: Centro de Investigaciones en Quimica Biologica de Cordoba (CIQUIBIC), UNC-CONICET, Dpto. de Quimica Biologica, Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Argentina.
 SOURCE: Development, growth & differentiation, (1997 Apr) 39 (2) 167-78.
 Journal code: 0356504. ISSN: 0012-1592.
 PUB. COUNTRY: Japan
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 OTHER SOURCE: GENBANK-U53214
 ENTRY MONTH: 199707
 ENTRY DATE: Entered STN: 19970805

Last Updated on STN: 20020212

Entered Medline: 19970724

AB Alpha tubulin can be post-translationally tyrosinated at the carboxy-terminus by a specific enzyme: tubulin tyrosine ligase. The expression of tubulin tyrosine ligase mRNA and protein during the development of rat skeletal muscle was examined in the present study. A portion of the coding region of the rat ligase cDNA was isolated and sequenced. The nucleotide and amino acid sequences showed about 90% homology with previously reported porcine and bovine ligase sequences. In newborn rats, ligase mRNA and protein were highly expressed in skeletal muscle. During early postnatal development, however, both ligase mRNA and protein dropped down dramatically. Quantitative measurements revealed that ligase protein at postnatal day 20 represented only 10% or less of the level at postnatal day 1. Ligase mRNA expression was also examined during the myogenesis in vitro. A strong ligase mRNA signal was detected in both undifferentiated myoblasts and cross-striated, contractile myotubes. The present results suggest that, during muscle differentiation, ligase function may be regulated by the amount of available mRNA. The discrepancy in the ligase expression between the in vivo and in vitro myogenesis suggests that factors controlling the levels of mRNA in vivo are lost in vitro.

L10 ANSWER 34 OF 41 MEDLINE on STN DUPLICATE 13
ACCESSION NUMBER: 93147125 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8093886
TITLE: Characterization of the tubulin-tyrosine ligase.
AUTHOR: Ersfeld K; Wehland J; Plessmann U; Dodemont H; Gerke V; Weber K
CORPORATE SOURCE: Max-Planck-Institute for Biophysical Chemistry, Department of Biochemistry, Goettingen, Germany.
SOURCE: Journal of cell biology, (1993 Feb) 120 (3) 725-32.
Journal code: 0375356. ISSN: 0021-9525.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-X68453
ENTRY MONTH: 199303
ENTRY DATE: Entered STN: 19930312
Last Updated on STN: 19980206
Entered Medline: 19930302

AB The sequence of tubulin-tyrosine ligase (TTL), the enzyme catalyzing the ATP-dependent posttranslational addition of a tyrosine to the carboxyterminal end of detyrosinated alpha-tubulin, has been determined. TTL from bovine and porcine brain was purified by immunoaffinity chromatography and extensively characterized by protein sequencing. Oligonucleotides derived from the protein sequence were synthesized and partial cDNA sequences were obtained using reversed transcribed brain mRNA in polymerase chain reactions. Polymerase chain reaction fragments were used to isolate a full-length cDNA clone from a randomly primed lambda gt10 cDNA library obtained from embryonic porcine brain mRNA. Porcine TTL is encoded by 1,137 nucleotides corresponding to 379 amino acid residues. It has a molecular weight of 43,425 and a calculated isoelectric point of 6.51. Northern blot analysis revealed a surprisingly long mRNA (approximately 6 kb in embryonic porcine brain). The protein sequence of TTL shares no extended homology with the sequences in the data banks. TTL contains a potential serine phosphorylation site for cAMP-dependent protein kinase (RKAS at positions 73 to 76). Residues 244 to 258 lie at the surface of the molecule. A rabbit antibody raised against a synthetic peptide corresponding to this sequence binds to native TTL. The same sequence contains the cleavage site for endoproteinase Glu-C (residue 248) previously shown to convert TTL into a nicked derivative in which the two fragments still form a tight complex but don't display enzymatic activity.

L10 ANSWER 35 OF 41 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 1992:70844 SCISEARCH
 THE GENUINE ARTICLE: HA993
 TITLE: POLYGLUTAMYLATED ALPHA-TUBULIN CAN ENTER THE TYROSINATION
 DETYROSINATION CYCLE
 AUTHOR: EDDE B (Reprint); ROSSIER J; LECAER J P; PROME J C;
 DESBRUYERES E; GROS F; DENOULET P
 CORPORATE SOURCE: COLL FRANCE, BIOCHIM CELLULAIRE LAB, 11 PL MARCELIN
 BERTHELOT, F-75231 PARIS 05, FRANCE (Reprint); CNRS, CTR
 RECH BIOCHIM & GENET CELLULAIRE, F-31062 TOULOUSE, FRANCE;
 CNRS, PHYSIOL NERVEUSE LAB, F-91198 GIF SUR YVETTE, FRANCE
 COUNTRY OF AUTHOR: FRANCE
 SOURCE: BIOCHEMISTRY, (21 JAN 1992) Vol. 31, No. 2, pp. 403-410.
 ISSN: 0006-2960.
 PUBLISHER: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036.
 DOCUMENT TYPE: Article; Journal
 FILE SEGMENT: LIFE
 LANGUAGE: English
 REFERENCE COUNT: 43
 ENTRY DATE: Entered STN: 1994
 Last Updated on STN: 1994

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB We have previously identified a major modification of neuronal
 alpha-tubulin which consists of the posttranslational addition of a
 varying number of glutamyl units on the gamma-carboxyl group of glutamate
 residue 445. This modification, called polyglutamylation, was initially
 found associated with detyrosinated alpha-tubulin [Edde, B., Rossier, J.,
 Le Caer, J. P., Desbruyeres, E., Gros, F., & Denoulet, P. (1990) Science
 247, 83-85]. In this report we show that a lateral chain of glutamyl
 units can also be present on tyrosinated alpha-tubulin. Incubation of
 cultured mouse brain neurons with radioactive tyrosine, in the presence of
 cycloheximide, resulted in a posttranslational labeling of six
 alpha-tubulin isoelectric variants. Because both tyrosination and
 polyglutamylation occur in the C-terminal region of alpha-tubulin, the
 structure of this region was investigated. [H-3]tyrosinated tubulin was
 mixed with a large excess of unlabeled mouse brain tubulin and digested
 with thermolysin. Five peptides, detected by their radioactivity, were
 purified by high-performance liquid chromatography. Amino acid sequencing
 and mass spectrometry showed that one of these peptides corresponds to the
 native C-terminal part of alpha-tubulin (VEGEGEEEGEEY)-V-440-Y-451 and
 that the remainders bear a varying number of glutamyl units linked to
 glutamate residue 445, which explains the observed heterogeneity of
 tyrosinated alpha-tubulin. A quantitative analysis showed that the
 different tyrosinated forms of alpha-tubulin represent a minor (13%)
 fraction of the total alpha-tubulin present in the brain and that most
 (80%) of these tyrosinated forms are polyglutamylated. The different
 forms of alpha-tubulin were found to be equal substrates for tubulin
 tyrosine ligase and tubulin carboxypeptidase, which
 indicates that alpha-tubulin can enter the tyrosination/detyrosination
 cycle independently of its degree of glutamylation.

L10 ANSWER 36 OF 41 MEDLINE on STN
 ACCESSION NUMBER: 89150728 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 3067795
 TITLE: Tubulin expression in trypanosomes.
 AUTHOR: Gallo J M; Precigout E
 CORPORATE SOURCE: Laboratoire de Biologie Cellulaire, URA CNRS 80, UFR
 Sciences, Poitiers, France.
 SOURCE: Biology of the cell / under the auspices of the European
 Cell Biology Organization, (1988) 64 (2) 137-43. Ref: 46
 Journal code: 8108529. ISSN: 0248-4900.
 PUB. COUNTRY: France
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198904
 ENTRY DATE: Entered STN: 19900306
 Last Updated on STN: 19900306

AB Microtubules in trypanosomes are the main component of the flagellar axoneme and of the subpellicular microtubule corset, whose relative positions determine the morphology of each cell stage of the life cycle of these parasites. Microtubules are polymers of tubulin, a protein dimer of two 55-kDa subunits, alpha- and beta-tubulin; in *Trypanosoma brucei*, the tubulin-coding sequences are clustered in a 40-kb fragment of tandemly repeated alpha- and beta-tubulin genes separated by a 170-bp intergenic zone. This cluster is transcribed in a unique RNA which is rapidly processed into mature mRNAs carrying the 5' 35-nucleotide leader sequence found in all trypanosome mRNAs. Although no heterogeneity has been found at the gene level, tubulin can be post-translationally modified in 2 ways: the C-terminal tyrosine of alpha-tubulin can be selectively cleaved and added again with 2 enzymes, tubulin carboxypeptidase and tubulin-tyrosine ligase; alpha-tubulin can also be acetylated on a lysine residue. Some molecular domains of tubulin are restricted to subpopulations of microtubules; for instance, the beta-tubulin form defined by the monoclonal antibody 1B41 is sequestered into a part of the subpellicular cytoskeleton limited to the flagellar adhesion zone, which might correspond to the group of 4 microtubules associated with a cisterna of the endoplasmic reticulum, forming the so-called "subpellicular microtubule quartet" (SFMQ). The early assembly of this zone in each daughter cell during the cell division of *T. brucei*, together with the alterations undergone by the domain defined by the monoclonal antitubulin 24E3 during the differentiation of *Trypanosoma cruzi*, suggest that specific tubulin forms are responsible for dynamic properties of SFMQ possibly involved in trypanosome morphogenesis.

L10 ANSWER 37 OF 41 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN

ACCESSION NUMBER: 1987-09146 BIOTECHDS

TITLE: Tubulin-tyrosine-ligase has a binding site on beta-tubulin: a 2-domain structure of the enzyme; hybridoma construction for monoclonal antibody production

AUTHOR: Wehland J; Weber K

CORPORATE SOURCE: Max-Planck-Inst.Biophys.Chem.

LOCATION: Max Planck Institute for Biophysical Chemistry, D-3400 Goettingen, Germany

SOURCE: J.Cell Biol.; (1987) 104, 4, 1059-67

CODEN: JCLBA3

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Using 2 distinct tubulin-tyrosine-ligase monoclonal antibodies, several subunit-specific tubulin monoclonal antibodies, and chemical crosslinking, a ligase binding site was identified on beta-tubulin. For production of the enzyme specific antibodies, 6-wk-old female BALB/c mice were immunized 3 times at 3 wk intervals with 100-200 ug affinity purified ligase emulsified in Freund's complete adjuvant for the first injection and Freund's incomplete adjuvant for the subsequent injections. The mice were tested for monoclonal antibody production, and spleen cells from the mouse with highest serum titer were fused with PA1 myeloma cells. Positive producing hybridomas were cloned twice by limiting dilution and monoclonal antibodies produced in ascites fluid in BALB/c mice. The binding site characterized is retained when the carboxy-terminal domains of both tubulin subunits are removed by subtilisin treatment. This explains the extreme substrate specificity of the enzyme, which does not act on other cellular proteins or carboxy-terminal peptides derived from detyrosinated alpha-tubulin. (42 ref)

L10 ANSWER 38 OF 41 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN

ACCESSION NUMBER: 1985-04125 BIOTECHDS

TITLE: Purification of brain tubulin-tyrosine-ligase by biochemical and immunological methods; monoclonal antibody preparation and hybridoma construction

AUTHOR: Schroeder H C; Wehland J; Weber K

CORPORATE SOURCE: Max-Planck-Inst.Biophys.Chem.

LOCATION: Institute for Physiological Chemistry, University of Mainz, D-6500 Mainz, Germany.

SOURCE: J.Cell Biol.; (1985) 100, 1, 276-81

CODEN: JCLBA3

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Tubulin-tyrosin-ligase (TTL) was purified biochemically from pig brain tissue to near homogeneity (over 95%). The purified enzyme, (10-20 ug) was then injected 3 times into Balb/c mice at intervals of 3 weeks. Freund's complete adjuvant and incomplete adjuvant were used for the first and last 2 injections respectively. Immune spleen cells were fused with PAI myeloma cells, and hybridomas were selected in HAT. Those secreting monoclonal antibody to TTL were cloned twice in soft agar. The antibodies specifically recognized TTL in brain and liver tissue of various mammals. Purified ascites IgG were coupled to CNBr-activated Sepharose 4B. TTL from crude brain extract selectively bound to this immunoaffinity column in 1.5 M NaCl and eluted with 3 M NaCl. The purity of the eluted TTL was over 95%. It was a monomeric protein of apparent mol.weight 40,000. It associated as a 1/1 complex with alpha-beta-tubulin on gradient centrifugation. (32 ref)

L10 ANSWER 39 OF 41 MEDLINE on STN

ACCESSION NUMBER: 84180758 MEDLINE

DOCUMENT NUMBER: PubMed ID: 6201294

TITLE: Organization of microtubules in stabilized meristematic plant cells revealed by a rat monoclonal antibody reacting only with the tyrosinated form of alpha-tubulin.

AUTHOR: Wehland J; Schroeder M; Weber K

SOURCE: Cell biology international reports, (1984 Feb) 8 (2) 147-50.

Journal code: 7708050. ISSN: 0309-1651.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198406

ENTRY DATE: Entered STN: 19900319

Last Updated on STN: 19900319

Entered Medline: 19840619

AB A rat monoclonal antibody against yeast tubulin (clone YL 1/2; Kilmartin et al., 1982) that reacts specifically with mammalian alpha-tubulin carrying a carboxyterminal tyrosine residue (Wehland et al., 1983) was used to localize microtubules in plant cells derived from onion root apices (*Allium cepa* L.). YL 1/2 reacted with all types of microtubular arrays known to occur in higher plant meristematic cells such as interphase cortical microtubules, pre-prophase bands, the mitotic spindle and phragmoplast microtubules. The specific labeling of microtubules in isolated cells from onion root tips by YL 1/2 indicates that plant cells like animal cells contain tubulin tyrosine ligase, the enzyme which posttranslationally modifies alpha-tubulin. This enzyme could be involved in the dynamic regulation of microtubular arrays in all eukaryotic cells.

L10 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1984:81418 HCAPLUS

DOCUMENT NUMBER: 100:81418

TITLE: State of tyrosination of soluble synaptosomal tubulin

AUTHOR(S): Barra, Hector S.; Arce, Carlos A.

CORPORATE SOURCE: Fac. Cienc. Quim., UNC, Cordoba, 5016, Argent.

SOURCE: Comunicaciones Biologicas (1983), 2(1), 13-18

CODEN: COBIEJ; ISSN: 0326-1956

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The presence of tubulin-tyrosine ligase and the state of tyrosination of tubulin in the soluble synaptosomal fraction from rat brain was studied. The ligase was present in this soluble fraction and the amts. of tyrosinated and nontyrosinated tubulin (expressed as nmol/mg protein) were similar to those in the cytosolic fraction.

L10 ANSWER 41 OF 41 EMBASE COPYRIGHT (c) 2005 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 79099794 EMBASE

DOCUMENT NUMBER: 1979099794
TITLE: Studies on NGF induced differentiation in PC12 pheochromocytoma cells. Specific rise in tyrosyl tubulin ligase activity induced by the nerve growth factor.
AUTHOR: Levi A.; Castellani L.; Calissano P.; et al.
CORPORATE SOURCE: Lab. Biol. Cell., CNR, Roma, Italy
SOURCE: Bulletin of Molecular Biology and Medicine, (1978) Vol. 3, No. SUPPL. 1, pp. 42s-50s.
CODEN: BMBMD5
COUNTRY: Italy
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
003 Endocrinology
029 Clinical Biochemistry
030 Pharmacology
LANGUAGE: English

AB A model system for the in vitro study of the mechanism of action of nerve growth factor (NGF) is described. The PC12 clonal line derived from a rat pheochromocytoma is shown to be very similar to the stem cell progenitor of both adrenal cromaffin cells and sympathetic neurones and to differentiate morphologically and physiologically like a nerve cell in response to NGF. Studies on tyrosyl tubulin ligase activity as a function of NGF induced differentiation in PC12 cells are reported.

=> d his

(FILE 'HOME' ENTERED AT 14:32:56 ON 06 OCT 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 14:33:23 ON 06 OCT 2005

L1 6829 S TESTIS(W)SPECIFIC
L2 428 S TYROSINE (W)LIGASE?
L3 3 S L1 AND L2
L4 2 DUP REM L3 (1 DUPLICATE REMOVED)
L5 7299296 S CLON? OR EXPRESS? OR RECOMBINANT
L6 89 S L2 AND L5
L7 20724 S "CPG ISLAND"
L8 12 S L6 AND L7
L9 10 DUP REM L8 (2 DUPLICATES REMOVED)
L10 41 DUP REM L6 (48 DUPLICATES REMOVED)

=> e feder j n/au

E1 101 FEDER J L/AU
E2 74 FEDER J M/AU
E3 183 --> FEDER J N/AU
E4 1 FEDER J N */AU
E5 16 FEDER JACK B/AU
E6 1 FEDER JAN DAVID/AU
E7 1 FEDER JEAN M/AU
E8 3 FEDER JEAN MARC/AU
E9 54 FEDER JEFFREY L/AU
E10 88 FEDER JENS/AU
E11 1 FEDER JOHANN/AU
E12 2 FEDER JOHANN G/AU

=> s e3

L11 183 "FEDER J N"/AU

=> e wu s/au

E1 2 WU RUYU/AU
E2 1 WU RYH LIH/AU
E3 3445 --> WU S/AU
E4 1 WU S */AU
E5 24 WU S A/AU
E6 85 WU S B/AU
E7 1611 WU S C/AU
E8 1 WU S C C/AU
E9 3 WU S C G/AU

E10 18 WU S C H/AU
E11 6 WU S C S/AU
E12 1 WU S C X P/AU

=> s e3

L12 3445 "WU S"/AU

=> e nelson t c/au

E1 6 NELSON T B/AU
E2 1 NELSON T BLAINE/AU
E3 127 --> NELSON T C/AU
E4 98 NELSON T D/AU
E5 621 NELSON T E/AU
E6 35 NELSON T E JR/AU
E7 50 NELSON T F/AU
E8 1 NELSON T F JR/AU
E9 38 NELSON T G/AU
E10 55 NELSON T H/AU
E11 12 NELSON T HOLLAND/AU
E12 2 NELSON T I/AU

=> s e3

L13 127 "NELSON T C"/AU

=> d his

(FILE 'HOME' ENTERED AT 14:32:56 ON 06 OCT 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS,
LIFESCI' ENTERED AT 14:33:23 ON 06 OCT 2005

L1 6829 S TESTIS(W)SPECIFIC
L2 428 S TYROSINE (W)LIGASE?
L3 3 S L1 AND L2
L4 2 DUP REM L3 (1 DUPLICATE REMOVED)
L5 7299296 S CLON? OR EXPRESS? OR RECOMBINANT
L6 89 S L2 AND L5
L7 20724 S "CPG ISLAND"
L8 12 S L6 AND L7
L9 10 DUP REM L8 (2 DUPLICATES REMOVED)
L10 41 DUP REM L6 (48 DUPLICATES REMOVED)
E FEDER J N/AU
L11 183 S E3
E WU S/AU
L12 3445 S E3
E NELSON T C/AU
L13 127 S E3

=> s l11 or l12 or l13

L14 3727 L11 OR L12 OR L13

=> s l2 and l14

L15 1 L2 AND L14

=> d all

L15 ANSWER 1 OF 1 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
AN 2004-07314 BIOTECHDS
TI New testis-specific tubulin tyrosine-ligase-like
BGS-42 polypeptide, useful for preventing, treating or ameliorating a
medical condition, e.g. aberrant cellular proliferation, reproductive
disorders or testicular disorders;
involving vector-mediated gene transfer, expression in host cell for
use in gene therapy
AU FEDER J N; WU S; NELSON T C
PA BRISTOL-MYERS SQUIBB CO
PI WO 2004005487 15 Jan 2004
AI WO 2003-US21605 9 Jul 2003
PRAI US 2002-394725 9 Jul 2002; US 2002-394725 9 Jul 2002
DT Patent

LA
OS
AB

English

WPI: 2004-099381 [10]

DERWENT ABSTRACT:

NOVELTY - A testis-specific tubulin tyrosine-ligase-like polypeptide, designated BGS-42 polypeptide, is new.

DETAILED DESCRIPTION - A testis-specific tubulin tyrosine-ligase-like polypeptide, designated BGS-42 polypeptide comprises or consists of: (a) a polypeptide fragment, domain, epitope or the full-length protein of a fully defined sequence of 541 amino acids (I), as given in the specification, or the encoded sequence included in ATCC Deposit Number PTA-4454, having tyrosine tubulin ligase activity; (b) a polypeptide comprising amino acids 2-541 of the sequence of (I), where the amino acids 2-541 comprises a polypeptide of (I) minus the start methionine; (c) a polypeptide comprising amino acids 1-541 or 73-365 of the sequence of (I); or (d) a polypeptide comprising at least 424 contiguous amino acids of the sequence of (I). INDEPENDENT CLAIMS are also included for: (1) an isolated nucleic acid molecule comprising or consisting of: (a) a polynucleotide fragment of 1838 bp (II), fully defined in the specification, or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II); (b) a polynucleotide encoding a polypeptide fragment, domain, epitope or the full-length protein of the sequence of (I), or a polypeptide fragment, domain or epitope encoded by the cDNA sequence included in ATCC Deposit Number PTA-4454, which is hybridizable to the sequence of (II), having tyrosine tubulin ligase activity; (c) a polynucleotide which is a variant or an allelic variant of (II); (d) nucleotides 156-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 2-541 of (I) minus the start methionine; (e) nucleotides 153-1775 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 1-541 of (I) including the start codon; (f) nucleotides 369-1247 of the sequence of (II), where the nucleotides encode a polypeptide corresponding to amino acids 73-365 of (I); (g) a polynucleotide that encodes at least 424 contiguous amino acids of (I); (h) at least 1272 contiguous nucleotides of (II); (i) a polynucleotide which represents the complementary sequence (antisense) of (II); (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides above, where the polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A or only T residues; (k) a polynucleotide comprising or consisting of the BGS-42 gene or BGS-42 promoter; or (l) a nucleotide sequence of 2241 bp, fully defined in the specification; (2) a recombinant vector comprising the isolated nucleic acid molecule; (3) an isolated antibody that binds specifically to BGS-42 polypeptide; (4) a recombinant host cell comprising the vector sequences, or expressing the BGS-42 polypeptide; (5) making an isolated polypeptide; (6) preventing, treating or ameliorating a medical condition; and (7) diagnosing a pathological condition or a susceptibility to a pathological condition in a subject.

WIDER DISCLOSURE - Also disclosed are screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides, and methods of controlling the expression of the polypeptide.

BIOTECHNOLOGY - Preparation (claimed): The BGS-42 polypeptide is prepared by standard recombinant methods. Making an isolated polypeptide comprises culturing the recombinant host cell under conditions such that the polypeptide is expressed, and recovering the polypeptide. Preferred Polypeptide: The full-length protein comprises sequential amino acid deletions from the C-terminus or the N-terminus. Preferred Nucleic Acid: The polynucleotide fragment consists of a nucleotide sequence encoding a human tyrosine tubulin ligase. Preferred Method: Preventing, treating or ameliorating a medical condition comprises administering to a mammalian subject a therapeutic amount of the BGS-42 polypeptide or its modulator. Diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprises determining the presence or absence of a mutation in the polynucleotide cited above, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation. Alternatively, the method comprises determining the presence or amount of expression of the BGS-42

polypeptide in a tyrosine tubulin ligase sample, and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

ACTIVITY - Cytostatic; Respiratory-Gen.; Gastrointestinal-Gen.; Neuroprotective; Endocrine-Gen.; Antiinflammatory; Anabolic; Hypertensive; Osteopathic; Nootropic; Antiparkinsonian; Antiarthritic; Antiasthmatic; Anti-HIV; Antibacterial; Immunosuppressive; Antiseborrheic; Dermatological. No biological data given.

MECHANISM OF ACTION - Tyrosine Ligase Modulator; Gene Therapy. No biological data given.

USE - The BGS-42 polypeptide or polynucleotide can be used for diagnosing a pathological condition or a susceptibility to a pathological condition in a subject, and for preventing, treating or ameliorating a medical condition, such as a disorder related to aberrant tubulin ligase activity, a disorder related to aberrant tubulin-carboxypeptidase activity, aberrant cellular proliferation, reproductive disorders, testicular disorders, testicular cancer, pulmonary disorders, lung cancer, gastrointestinal disorders, colon cancer, stomach cancer, neural disorders, brain cancer, liver cancer, or proliferative condition of the testis, lung, small intestine, brain or lymph tissue (all claimed). The BGS-42 polypeptide, polynucleotide, or their modulators are also useful for treating infertility, Cushing's syndrome, emphysema, pneumonia, Addison's disease, acromegaly, Alzheimer's disease, or Parkinson's disease. The BGS-42 polypeptide can be used as a preventive agent for immunological disorders including arthritis, asthma, AIDS, sepsis, acne, Sjogren's disease or scleroderma. The antibodies may be used to purify, detect and target the BGS-42 polypeptides.

ADMINISTRATION - Administration of the antibody is 0.1-100 (preferably 1-10) mg/kg, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, intranasally, epidurally, intraventricularly, intrathecally, topically, orally, or rectally.

EXAMPLE - A polynucleotide encoding a BGS-42 polypeptide was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence to synthesize insertion fragments. The pQE-9 vector was digested with BamHI and XbaI and the amplified fragment was ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial ribosome-binding site. The ligation mixture was used to transform Escherichia coli strain M15/rep4. Transformants were identified by their ability to grow on LB (Luria bertani) plates, and ampicillin/kanamycin-resistant colonies were selected. Clones containing the desired constructs were grown overnight in liquid culture, i.e. LB media, supplemented with both ampicillin and kanamycin. Isopropyl-B-D-thiogalacto pyranoside (IPTG) was added to induce gene expression. Cells were grown for an extra 3-4 hours, and cells were harvested by centrifugation. The cell pellet obtained by centrifugation was solubilized, and the solubilized BGS-42 protein was purified using a metal chelating column under conditions that allow tight binding of the protein. (343 pages)

CC THERAPEUTICS, Protein Therapeutics; GENETIC TECHNIQUES and APPLICATIONS, Gene Expression Techniques and Analysis; DISEASE, Cancer; DISEASE, Central Nervous System; DISEASE, HIV and Other Virus Infections; DISEASE, Other Diseases; DIAGNOSTICS, Molecular Diagnostics; THERAPEUTICS, Gene Therapy

CT RECOMBINANT TESTIS-SPECIFIC TUBULIN TYROSINE-LIGASE
-LIKE PROTEIN PREP., ISOL., VECTOR-MEDIATED GENE TRANSFER, EXPRESSION IN HOST CELL, APPL. CANCER, REPRODUCTIVE DISORDER, TESTICULAR DISORDER, PULMONARY DISORDER, GASTROINTESTINAL DISORDER, NEURAL DISORDER, IMMUNOLOGICAL DISORDER, ARTHRITIS, ASTHMA, AIDS, SEPSIS, ACNE DIAGNOSIS, THERAPY, GENE THERAPY PROTEIN TUMOR (23, 14)

=> d his

(FILE 'HOME' ENTERED AT 14:32:56 ON 06 OCT 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 14:33:23 ON 06 OCT 2005

L1 6829 S TESTIS(W)SPECIFIC

L2 428 S TYROSINE (W) LIGASE?
L3 3 S L1 AND L2
L4 2 DUP REM L3 (1 DUPLICATE REMOVED)
L5 7299296 S CLON? OR EXPRESS? OR RECOMBINANT
L6 89 S L2 AND L5
L7 20724 S "CPG ISLAND"
L8 12 S L6 AND L7
L9 10 DUP REM L8 (2 DUPLICATES REMOVED)
L10 41 DUP REM L6 (48 DUPLICATES REMOVED)
E FEDER J N/AU
L11 183 S E3
E WU S/AU
L12 3445 S E3
E NELSON T C/AU
L13 127 S E3
L14 3727 S L11 OR L12 OR L13
L15 1 S L2 AND L14

	Issue Date	Pages	Document ID	Title
1	20050602	71	US 2005011866 5 A1	Methods for conducting assays for enzyme activity on protein microarrays
2	20040902	199	US 2004017113 1 A1	Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42
3	20040812	171	US 2004015723 4 A1	Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42
4	20040701	105	US 2004012676 2 A1	Novel compositions and methods in cancer
5	20040617	174	US 2004011667 0 A1	Cytoskeleton-associated proteins
6	20040520	106	US 2004009682 8 A1	Cytoskeleton-associated proteins
7	20040122	250	US 2004001405 3 A1	Novel proteins and nucleic acids encoding same
8	20040108	165	US 2004000556 0 A1	Novel full-length cDNA
9	20031225	178	US 2003023639 2 A1	Novel full length cDNA
10	20031211	206	US 2003022857 0 A1	Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection

11	20030529	34	US 2003009992 5 A1	Yeast arrays, methods of making such arrays, and methods of analyzing such arrays
----	----------	----	--------------------------	---

	Issue Date	Page s	Document ID	Title
12	20030320	196	US 2003005442 1 A1	Nucleic acids, proteins, and antibodies
13	20030306	24	US 2003004486 6 A1	Yeast arrays, methods of making such arrays, and methods of analyzing such arrays
14	20050913	138	US 6943241 B2	Full-length cDNA
15	20040831	93	US 6783969 B1	Cathepsin V-like polypeptides

	Issue Date	Page s	Document ID	Title
1	20040902	199	US 2004017113 1 A1	Polynucleotides encoding a novel testis-specific tubulin tyrosine- ligase-like protein, BGS42
2	20040812	171	US 2004015723 4 A1	Polynucleotides encoding a novel testis-specific tubulin tyrosine- ligase-like protein, BGS42
3	20040701	105	US 2004012676 2 A1	Novel compositions and methods in cancer
4	20040122	250	US 2004001405 3 A1	Novel proteins and nucleic acids encoding same
5	20031211	206	US 2003022857 0 A1	Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
6	20030320	196	US 2003005442 1 A1	Nucleic acids, proteins, and antibodies
7	20040831	93	US 6783969 B1	Cathepsin V-like polypeptides

	Issue Date	Page s	Document ID	Title
1	20040902	199	US 2004017113 1 A1	Polynucleotides encoding a novel testis-specific tubulin tyrosine- ligase-like protein, BGS42
2	20040812	171	US 2004015723 4 A1	Polynucleotides encoding a novel testis-specific tubulin tyrosine- ligase-like protein, BGS42

	L #	Hits	Search Text
1	L1	0	testis adj specific adj tyrosine adj kinase\$2
2	L2	2	"BGS42"
3	L3	7761 68	clon\$3 or express\$3 or recombinant
4	L4	15	tyrosine adj ligase\$2
5	L5	653	"CpG island"
6	L6	0	14 and 15
7	L7	1631 15	WU FEDER NELSON
8	L8	7	14 and 17